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Despite advances in the early detection and treatment of breast cancer, it remains a challenge to identify 
which patients may experience a poor prognosis or respond poorly to treatment. Familial predisposition is a 
major risk factor of breast cancer and, perhaps, a modifier of patients’ survival. There is also evidence 
suggesting that hereditary factors may impact a patient’s response to treatment. However, the magnitude of 
the effect, and the molecular mechanism behind it, is largely unknown.  
In Finland, over 4,000 women on average are annually diagnosed with breast cancer and the majority of 
them undergo chemotherapy; they may or may not respond to the treatment. It is challenging to identify 
germline markers and tumor molecular profiles, which objectively predict prognosis and treatment response, 
and translate this information into cancer therapy.  
The aim of this thesis was to identify prognostic and predictive markers in breast cancer by investigating 
cancer-related networks as well as candidate genes of regulatory networks in invasive breast cancer cases. 
Taking both a network analysis approach as well as a candidate gene study, clinicopathological and survival 
association analyses were performed to (I) study the association of germline variations in TP53 network 
genes with breast cancer patients’ survival and treatment outcome; (II) investigate the impact of two-SNP 
interaction of NF-κB signaling network on predicting patients’ survival; (III) evaluate the association of 
NQO1 protein expression and NF-κB activation with clinicopathological features of the tumors, patients’ 
survival, and treatment outcome; and (IV) study the role of the miR-30 family in breast cancer patients’ 
survival and drug response. 
The germline variations were studied in collaboration with the Breast Cancer Association Consortium 
(BCAC). In Study I, the variations were initially analyzed in a set of DNA samples from 925 invasive breast 
cancer cases from Helsinki Breast Cancer Study (HEBCS) included in BCAC, and were further analyzed in 
pooled data of 4,701 cases from four independent studies (including HEBCS) contributing to BCAC. In 
Study II, the germline variations were studied in extensive pooled data of 30,431 cases from 24 independent 
studies participating in BCAC. In Studies III and IV, the tumor samples for immunohistochemical and 
miRNA in situ hybridization of 1,240 cases were from two series of 884 unselected Finnish invasive breast 
cancer patients and an additional 542 familial cases. Gene expression analysis was performed using 
microarray data of total RNA from 187 fresh frozen primary breast cancer tumors. Drug sensitivity screening 
tested the influence of miR-30 family members on the response of human breast cancer cell lines to two 
drugs, doxorubicin and lapatinib. 
In Study I, a significant interaction effect was found between germline variations in TP53-related 
genes, PRKAG2 (rs4726050) and MDM2 SNP309, with PRKAG2 (rs4726050) rare G allele showing a dose-
dependent impact for superior breast cancer survival only among the MDM2 SNP309 rare G allele carriers. 
Also, PPP2R2B (rs10477313) rare A allele predicted increased survival after hormonal therapy. Further 
studies are warranted to clarify the impact of PRKAG2 and PPP2R2B on patients’ survival.  
In Study II, the SNP-SNP interaction test in the NF-κB activating pathway found two interacting SNP pairs, 
rs5996080-rs7973914 and rs17243893-rs57890595, which was associated with patients’ survival under 
recessive and dominant models of inheritance, respectively. While rs5996080 and rs7973914 were included 
in the study for representing the haplotype block harboring NF-κB activating genes, BAFFR and TNFR1/3, 
they physically reside in SREBF2 and SCNN1A, thus, the interacting effect found between these two loci 
may represent either of the genes. The dominant SNP pair, rs17243893 and rs57890595, represented TRAF2 
and TRAIL-R4. Based on the published function of the interacting genes, and the in silico analysis of this 
study, the survival association of the identified SNP pairs may be a result of interplay between these gene 
pairs and their downstream influence on the dynamic of canonical and non-canonical NF-κB pathways.  
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In Study III, the immunohistochemical staining analysis of NQO1 expression and NF-κB nuclear localization 
(inferred activity) did not find significant association between either of the proteins and patients’ survival or 
treatment outcome. However, an inverse correlation between NQO1 expression and NF-κB activity was 
observed in breast cancer tumors. The NQO1/NF-κB inverse correlation was also reflected in their 
association with ER status, as well as their correlation with gene expression.  
In Study IV, a significant association was found between the high expression of miR-30d and longer 
metastasis-free survival, particularly in subgroups of patients with high proliferative tumors, ER negativity, 
HER2 positivity, and among those who received chemotherapy. However, the high expression of miR-30 
appeared to also correlate with the characteristics of aggressive tumors, i.e. higher grade, positive nodal 
status, and high proliferation (estimated by high Ki67). In a drug sensitivity screening test of all miR-30 
family members, miR-30a–e sensitized the human breast cancer cell lines to doxorubicin. Also, in the HER2-
positive HCC1954 cell line, miR-30d sensitized the cells to lapatinib. The pathway enrichment analysis of 
miR-30 family members in the METABRIC gene expression dataset revealed that high levels of miR-30 
family occurred simultaneously with low expressions of genes involved in cell movements, consistent with 
the observed association with longer metastasis-free survival. 
The result of this work suggests prognostic/predictive potentials for candidate genes in cancer-related 
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Gene names are written in italics. 
AKT 
APC  
AKT serine/threonine kinase 1 
APC, WNT signaling pathway 
AT  ataxia telangiectasia  
ATM  
BARD1  
ataxia telangiectasia mutated  
BRCA1 associated RING domain 1 
BCAC Breast Cancer Association Consortium 
BAFFR B-cell activating factor receptor 
BRCA1  breast cancer gene 1  
BRCA2  breast cancer gene 2  




BRCA1 interacting protein 1  
cyclin G1 
checkpoint kinase 2 
CI  confidence interval  
CISH  chromogenic in situ hybridization  
CMF  cyclophosphamide, methotrexate, and 
fluorouracil  














estrogen receptor  
hazard ratio 
fluorescence in situ hybridization 
human epidermal growth factor receptor 2 
gene expression 
genome-wide association study 
metastasis at time of diagnosis 
mouse double minute 2 homolog 
mutL homolog 1 
nodal status 
nuclear factor kappa B 
NAD(P)H:quinone oxidoreductase 
progesterone receptor 
PIAS1 protein inhibitor of activated Stat1 
PPP2R2B 
PR 
PP2A, regulatory subunit B, beta isoform 
progesterone receptor 
PRKAG2 AMP-activated protein kinase γ2 subunit 
PTEN phosphatase and tensin homolog 
SNP single-nucleotide polymorphism 
T tumor size 
TNFR1 TNFR superfamily member 1 
TNFR3 TNFR superfamily member 3 
TOP2A topoisomerase II alpha 
TP53 tumor protein p53 
TRAIL-R4 TNF-related apoptosis ligand receptor 4 







Breast cancer is the most frequently diagnosed cancer among women worldwide, accounting 
for more than 1 in 10 new cancer cases (Bray et al., 2018). Familial predisposition is a 
significant breast cancer risk factor. Women with two or more breast cancer patient relatives 
have a 2.5-fold increased risk of developing the disease.  
The mortality rate of breast cancer has been decreased since the early 1990s thanks to early 
detection and significant advances in cancer treatment (Brewer et al., 2017). Breast cancer 
prognosis varies considerably based on the characteristics of the tumor, and is highly dependent 
on clinical and pathological factors such as the status of axillary lymph nodes, the expression of 
estrogen receptor (ER) or HER2 and the status of metastasis. The ER and HER2 status also 
assist the therapy decisions, i.e. ER-positive tumors are responsive to hormonal therapy, such 
as tamoxifen, and HER2-positive tumors are more likely to respond to anti-HER2 agents, such 
as trastuzumab and lapatinib. If clinically appropriate, both groups may also receive 
chemotherapy. Patients without hormone receptor or HER2 positivity only receive 
chemotherapy. However, many patients do not respond to therapy and a significant number of 
responsive patients will eventually develop drug resistance (Waks & Winer, 2019). Therefore, 
additional reliable biomarkers are required to identify patient groups with poor prognosis and to 
predict and facilitate therapeutic decision-making, which in turn leads to improved cancer 
management and better patient care.  
While the impact of germline mutation on breast cancer risk is rather well established (Brewer 
et al., 2017), the contribution of the hereditary component to the prognosis of breast cancer and 
the molecular mechanism behind it is yet to be elucidated. However, germline variations in 
candidate cancer-related genes have been suggested to associate with patients’ survival.  
This thesis studied an extensive set of invasive breast cancer patients to investigate the 
germline variations in cancer-related pathways (i.e. TP53 and NF-κB), and expression of 
regulatory elements (i.e. miR-30 family), for their association with patients’ survival, also 
stratified by patient subgroups based on features of the tumor, and with treatment outcome, as 
well as their correlation with the clinicopathological feature of the tumors. Additionally, a drug 
sensitivity screening tested the impact of the miR-30 family on sensitizing the breast cancer 





2 Review of the literature 
2.1  Cancer 
Cancer is the second cause of death following heart disease. The global burden of cancer is 
increasing due to sociodemographic and lifestyle changes, as well as the aging of the world 
population. Nearly 18 million new cancer cases were registered worldwide in 2018; of these, 9.4 
million were male and 8.6 million were female. A total of 9.4 million deaths due to cancer are 
estimated to have occurred in 2018, including 5.3 million male and 4.1 million female. Lung, 
breast, and colorectum are the most frequent cancer sites and the leading cause of cancer death 
(Globocan http://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf). 
Cancer arises from genetic mutation in the DNA, which occurs for a variety of reasons. The most-
studied known or suspected risk factors for cancer include age, alcohol, cancer-causing substances, 
chronic inflammation, diet, heredity, hormones, immune suppression, infectious agents, obesity, 
radiation, sunlight, and tobacco. Also, about 15% of cancers stem from viral infections, e.g. human 
papillomavirus. Some cancer risk factors are uncontrollable, such as aging and heredity, and some 
are controllable, such as tobacco products, sunlight, and diet. Although many cancers are not 
preventable, a major reduction in cancer associated mortality is achievable through early detection 
(and changes in lifestyle), for instance, cervical, breast and prostate cancers can be slowed or even 
eradicated with early detection (Allemani et al., 2018).  
 
2.1.1 Tumorigenesis and the biology of cancer 
For the living organism to grow, repair, and reproduce, cells need to retain the ability to replicate 
and divide. The process of cell division is a small fraction of the cell cycle in which the DNA 
molecules duplicate and segregate into daughter cells under a well-orchestrated replication 
mechanism. Despite the elaborate genome maintenance systems that control the replication 
machinery, cells may deviate from the normal constraints of division and proliferate uncontrollably, 
which results in tumor formation. Tumors which are not cancerous are known as benign; cancers 
that grow locally without spreading to surrounding tissues are classified as carcinoma in situ; and 
those with the ability to invade neighboring tissues and spawn metastasis through the body are 
described as malignant, commonly known as cancerous. Benign tumors are rarely life threatening; 
however, they can cause clinical problems if their expansion causes them to press on vital structures 
(e.g. blood vessels, nerves), or if they cause the over-release of hormones (e.g. excessive release of 
thyroid hormone). In general, benign tumors are often slow growing in nature, and more 
differentiated compared to the cancerous tumors. 
Cancer can originate from almost all cell types, however, the most common human cancers rise 
from epithelial cells — the carcinomas. Based on their shape and biological function, normal 
epithelia and the carcinomas originating from them fall into two categories of squamous cell 
carcinoma and adenocarcinoma. Squamous cell carcinomas, such as the keratinocyte carcinoma of 
the skin, arise from the often-flattened epithelial sheets lining the top layer of skin, cavities, and 
channels to protect the underlying tissues. Adenocarcinomas form in the substance-secreting glands 
and are commonly found in the breast, colon, pancreas, stomach, prostate, endometrium, and ovary. 
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Epithelia in the lung, uterus, and cervix have the capability to transform into adenocarcinoma or 
squamous cell carcinoma or both. As for non-epithelial malignant tumors, the major classes include 
(1) sarcomas, which arise from mesenchymal connective tissues that make up bones, as well as soft 
tissues such as muscles, tendons, and blood vessels, (2) hematopoietic cancers, which originate 
from the precursors of blood-forming tissues, including the cells of the immune system, and (3) 
neuroectodermal malignant tumors, which emerge from the central and peripheral nervous system. 
From the completely benign to the highly malignant, tumors represent an increasing degree of tissue 
abnormality, which suggests that tumor progression is a multistep process. For a normal cell to 
transform to cancer, it must acquire generic tumorigenic competence, also described as a hallmark 
of cancer (Hanahan & Weinberg, 2011). The hallmarks of cancer include sustaining proliferative 
signaling, i.e. applying alternative mechanisms that may deregulate division and growth signals in 
order to operate chronic proliferation and thus tumor initiation and growth. Excessive proliferation 
also involves evading growth suppressors, as well as protecting incipient cancer cells from 
programmed cell death, termed apoptosis. Of the diverse strategies tumor cells evolve to attenuate 
the apoptosis circuitry, the most common is the loss of tumor protein p53 (TP53), a tumor 
suppressor function which will be discussed in section 2.5. 
In normal cells, the replication rate is controlled also through the length of telomeric DNA: the 
telomere length declines upon each cell generation until it becomes too short to protect the 
chromosome end, which results in either replicative senescence or crisis. To enable replicative 
immortality, tumor cells must maintain a sufficient length of telomere and avoid crisis-induced cell 
death. Further, as the cancer cells proliferate and become more aggressive, they also enable 
angiogenesis — i.e. blood vessel formation — to grant nutrition, oxygen and waste disposal. When 
this occurs, the tumor is referred to as invasive, because the cells can now break off and enter the 
blood stream and invade other tissues and organs; this co-opt developmental process is termed 
metastasis.  
Invasion and metastasis are the essential differences between the benign, and often harmless, 
tumors and the cancerous ones. They count for virtually 90% of cancer death and represent the 
major unsolved problem of cancer pathogenesis. The majority of small tumors are destroyed by the 
innate immune system. However, occasionally tumor cells evade detection and destruction by the 
immune system, to become more fit and survive in their host. To grow beyond their limit size, 
cancer cells divide rapidly, thus, compared to their generally quiescent cells of origin, they need 
more energy, oxygen, and biomaterials. In the past decade, it became increasingly clear that cancer 
cells reprogram their energy metabolism. However, whether reprogramming the energy metabolism 







2.1.2 Cancer genes and mutations  
Mutations in cancer genes enhance cancer risk or promote cancer development. Traditionally, 
cancer genes involve two types of growth-controlling genes: (1) oncogenes which promote cell 
growth and/or motility and are usually upregulated in cancer cells, and (2) tumor suppressor genes 
which suppress cell growth and/or motility and are frequently deactivated in cancer cells (Ponder, 
2001; Weinberg, 1989). 
Oncogene mutations contributing to cancer are typically gain-of-function mutations which render 
the gene over-activation or activation under conditions in which the wild-type gene is silent. 
Oncogene activation is driven from various types of mutations, including genomic rearrangement 
and chromosomal translocations (e.g. the MYC gene family), gene amplification (e.g. ERBB2 also 
known as HER2/neu), and base substitution/insertion/deletion (e.g. PIK3CA), which either directly 
result in over expression of the cancer-contributing gene or impact its regulation and activation 
process. It appears that a single oncogene activating mutation is enough to provide unlimited 
growth advantage to the cell, in spite of the continued presence of a wild-type allele. However, the 
growth advantage rendered by oncogenes can be impaired by inactivation of a single oncogene, a 
phenomenon referred to as oncogene addiction, which provides therapeutic potentials (Weinstein & 
Joe, 2008). Although oncogenes are dominant mutations, it is worthy of note that cancer is a 
multistep mutation process, and single mutations may develop tumor but are not typically sufficient 
to produce cancer. While a single oncogene mutation is sufficient to develop cancer in immortalized 
laboratory cells which are already sensitive to oncogenes, we know now that an accumulation of 3-
20 driver mutations are required to make a fully developed cancer in normal cells in a human’s 
body (Tomasetti et al., 2015). 
The partial or total inactivation of the tumor suppressor genes is typically the result of loss-of-
function mutations, whereas gene amplification and chromosomal translocation are rarely found in 
these genes. The inactivation is frequently driven from truncation of the gene open reading frame 
(ORF) through nonsense mutation, small insertion/deletion, or splice site mutation. Loss-of-
function mutation in tumor suppressor genes generally act recessively at the cellular level, which 
means that the mutated allele is masked by the wild-type allele and therefore, as suggested in 
Knudson’s “two-hit” hypothesis (Knudson, 1971), the cellular phenotype of a mutated tumor 
suppressor only manifests when both alleles are altered. An exception to this mechanism is another 
pathological phenotype referred to as haploinsufficiency, where one wild-type allele is not adequate 
to carry out the protein function (e.g. BRCA1-haploinsufficiency). An additional exception is the 
non-mutational impairment of the wild-type allele referred to as the dominant negative effect of the 
mutated allele which blocks the function of the wild-type one. Dominant negative effect is common 
in TP53 pathogenesis caused by missense mutation (Srivastava et al., 1993).  
Every tumor carries thousands of genetic and epigenetic mutations, however, only a very small 
portion of these mutations render the tumor cell a growth advantage over the surrounding cells. 
Based on their tumorigenic consequences, the mutations are identified as driver and passenger. 
Driver mutations endow the tumor cells an essential fitness advantage in their microenvironment, 
and thus are selected during clonal evolution. Passenger mutations provide no such benefit and 
occur by chance before or during the process of tumorigenesis and can also be found in normal 
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proliferative tissues. Since the vast majority of mutations (97%) (Lawrence et al., 2014) in cancer 
are passengers, it is challenging to distinguish them from driver mutations. There is no compelling 
evidence to suggest that the accumulation of passenger mutations contributes to tumor progression, 
but whether they are deleterious to cancer growth and metastasis remains to be concluded (Stratton, 
Campbell & Futreal, 2009; McFarland et al., 2017). 
Another classic categorization of tumor suppressor genes includes:  
(1) gatekeepers which directly suppress cell outgrowths and, if mutated, highly elevate the risk 
of tumor development. The characteristic example includes the gatekeeping mutation in 
APC which associates with the initiation of colorectal cancer;  
(2) caretakers which participate in DNA repair to maintain genome stability. Examples of 
caretaker genes are the breast cancer susceptibility genes BRCA1 and BRCA2; 
(3) landscapers which maintain the normal tissue architecture and homeostasis and when 
mutated result in a tumor-prone microenvironment defect. For instance, mutation in SMAD4 
contributes to formation of colorectal cancer by altering the tissue structure of colorectal 
mucosa and therefore providing a tumor-prone landscape (Vogelstein et al., 2013; Kinzler & 
Vogelstein, 1997). 
In the context of genetics, the human body consists of two types of cells: germ cells and somatic 
cells. Germ cells are the cells of the reproductive system, which give rise to female and male 
gametes, also known as oocyte and sperm, respectively. All other cells in the body are somatic cells. 
If the cancer gene mutation arises in the lineage of germ cells (the germline) it will be carried in 
every cell of the individual who inherited it, whereas if the cancer gene mutation arises in the 
somatic cells, the mutation is not passed through generations. In this context, the mutations in 
cancer genes are either acquired through inheritance via the germline, or spontaneously via somatic 
mutation or virus infection. Although germline mutations in cancer susceptibility genes 
significantly increase the cancer risk in individuals who inherit them, they impart only a subset of 
all cancer risks. The heritable mutations discovered in germlines are attributable primarily to tumor 
suppressor genes, whereas nearly all mutations that convert proto-oncogenes to oncogenes are 
acquired by somatic mutations and, in general, are not identified in the germline of a cancer-prone 
family. Thus, they are unlikely to play a major role in hereditary cancer predisposition, which will 
be described in the following section (Ponder, 2001; Oosterhuis & Looijenga, 2019).  
 
2.1.3 Hereditary predisposition to cancer  
An entire set of genes is identified whose mutations contribute to hereditary cancer syndromes. 
However, the degree of penetrance — that is, the likelihood of cancer development conferred by 
these genes — varies+. During the 1980s and 1990s, linkage analysis and positional cloning 
resulted in identification of highly penetrant cancer susceptibility genes, including BRCA1 and 
BRCA2 (for breast and ovarian cancer), APC (for colorectal cancer), MSH1 and MLH2 (for Lynch 
syndrome), and CDKN2A (for melanoma); most of these are involved in DNA damage repair or cell 
cycle control (Foulkes, 2008; Easton et al., 2015). The high penetrance cancer associated mutations 
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are infrequent and their prevalence varies between populations, and they only explain a subset of 
cancer heritability. Presumably there are other germline cancer genes which impact overall cancer 
risk but, due to the lesser penetrance they confer, their attributable risk is difficult to quantify, and 
they are hard to identify by linkage analysis due to incomplete familial segregation. Alternative 
approaches — such as candidate gene studies and GWAS — were therefore applied to facilitate the 
discovery of moderate and low penetrant cancer genes which, despite their presence also in the 
general population, may impact the individual’s risk and survival after breast cancer (Michailidou et 
al., 2013, 2017). 
In addition to penetrance and attributable risk, the impact of inheriting germline cancer genes is 
assessed by several metrics. These commonly include the relative risk (risk ratio), which is the 
probability of cancer occurring in mutation carriers divided by the probability of cancer occurring in 
the general population; and the odds ratio, which represents the efficacy of the mutant allele in 
developing cancer and is measured by the odds that an individual with the mutation develops cancer 
divided by the odds of an individual without the mutation developing cancer. The importance of 
assessing cancer risk (and survival) in individuals with a family history of cancer is manifested in 
the success of cancer screening, available genetic testing, and counseling in oncology clinics and 
clinical genetics departments. These productive approaches promote the early detection of cancer, 
and thus reduce the cancer caused mortality rate. Additionally, they aid the process of decision 
making in taking aggressive preventive measures such as breast mastectomy. While cancer 
treatment is the major field of study in cancer research, in the future we hopefully have fewer 
cancers to treat because we will be able to prevent some (Merkow et al., 2017).  
  
2.2 Breast cancer  
2.2.1 Epidemiology  
Breast cancer is by far the most commonly diagnosed neoplasm in women and the leading cause of 
cancer death among women worldwide (Figure 1). Breast tumors occur in men too, but much less 
frequently than in women. In 2018, about 2 million new cancer cases were diagnosed among 
women worldwide (Globocan http://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-
sheets.pdf). The overall breast cancer incidence rate (i.e. the number of newly diagnosed cases in a 
given time period) is higher in developed countries and, traditionally, lower in many low–middle 
income countries. The diversity of incidence rates implicates the difference in awareness, 
prevalence, adequate screening methods, and lifestyle-related risk factors such as obesity, smoking, 
reproductive patterns, hormonal therapy after menopause, etc. However, economic transitions, 
recent changes in reproductive patterns (such as later age at first childbirth), and fewer childbirths 
appear to increase the incidence rate in low–middle income countries. The mortality rate, too, varies 
globally due to the availability of resources which impact survival rate by influencing the 
prevention, early detection, and treatment approaches. The current five-year survival rate is 85% or 
higher in high income countries and 60% or lower in most low–middle income countries, primarily 
due to late detection and inadequate health services (Allemani et al., 2015). In Finland, 4,961 new 
breast cancer cases were diagnosed in 2016, which account for almost 32% of all new cancer cases 
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in the country. Figure 2 illustrates the trends of cancer incidence (2a) and mortality (2b) rates 
among women in Finland between 1953 and 2016.  
 
 
Figure 1. Top: most common cancer site per country, estimated age standardized incidence rate (world), 
2018, females, all ages. Bottom: most common cancer site per country, estimated age standardized mortality 






Figure 2. Top: New cancer cases diagnosed among Finnish women during 1953 to 2016, rate per 100,000, 
age standardized (Finland 2014). Bottom: Death due to cancer among Finnish women diagnosed between 






The human breast (both female and male) contains mammary glands which are able to produce and 
eject milk. During puberty and pregnancy, female mammary glands undergo extensive postnatal 
development and expansion in response to stimulation by hormones such as estrogen, progesterone, 
and prolactin. The breast is composed of skin, hypodermis (fat and connective tissue with blood 
vessels and nerves), and breast tissue. The breast tissue is made up of epithelial parenchyma and the 
stromal elements. The milk production site of the breast consists of 15–20 lobes which further 
divide into 20–40 lobules composed of branched tubulo-alveolar glands. The lobes are connected by 
a ductal system which transports milk into the endpoint of the nipples. The lobules and ducts are 
lined with epithelial cells from which the majority of breast cancers arise. The size and perfusion of 
the mammary glands undergo extensive changes during thelarche, menstruation, pregnancy, 
lactation, menopause, and through aging. Under the stimuli of the pituitary and ovarian hormones, 
the breast tissue progressively develops and differentiates. The estrogen and progesterone receptor 
content of the breast impacts the proliferation activity, and therefore the risk of accumulation of 
DNA replication errors and cancer development. The proliferation activity is rapid especially 
between menarche and first childbirth, and declines with the terminal differentiation in the first full-
term pregnancy (Li et al., 2008).  
Whether or not a woman develops breast cancer is influenced by multiple factors including genetic 
predisposition and family history, history of mammary gland disease, age, hormones, early 
menarche, late child-bearing, age at menopause, and lifestyle. Women with one first-degree relative 
affected by breast cancer have a 1.8-fold higher risk of developing breast cancer compared to 
women who have no affected relatives. The risk increases to 2.93 and 3.9, respectively, for women 
with two and three or more first-degree relatives affected by breast cancer (Collaborative Group on 
Hormonal Factors in Breast Cancer, 2001b). The likelihood of developing breast cancer increases 
through aging, which can be described, partly, by the accumulation of mutations. Further, breast 
tissue exposure to endogenous levels of estrogen and progesterone throughout reproductive years, 
as well as factors related to hormone levels, can influence the risk of breast cancer. For instance, for 
every year younger at menarche, the breast cancer risk increases by a factor of 1.05, and for every 
year older at menopause it increases by a factor of 1.03 (Collaborative Group on Hormonal Factors 
in Breast Cancer, 2012). Also, giving birth when younger than 24 years old seems to decrease the 
lifetime risk of breast cancer by 7%; however, the pattern appears to reverse for first pregnancy 
after age 35. The protective pattern is exhibited for prolonged breastfeeding, that is, every 12 
months of breastfeeding decreases the risk of developing neoplastic disease by 4.3% (Collaborative 
Group on Hormonal Factors in Breast Cancer, 2002). It has been suggested that long-term exposure 
to exogenous estrogen, mainly through oral contraceptives and post-menopausal hormone 
replacements, might increase the risk of breast cancer. Mammographic density may affect cancer 
risk. An overview of 42 studies suggested that women with 70% or higher density have a 4.64-fold 
higher risk of developing cancer compared with women with less than 5% density (McCormack & 
dos Santos Silva, 2006; Duffy et al., 2018). Additional relevant elements involve lifestyle factors 
such as smoking, alcohol consumption, excess body weight, and physical inactivity. Although 
environmental factors may not have the same effect on everyone due to genetic heterogeneity, 
strong observational breast cancer risk association makes weight control, exercise, and moderation 
of alcohol intake advisable (Howell et al., 2014). The abundance of the above-mentioned risk 
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factors indicates the multi-directionality of the concept and studies investigating it. Yet, in a 
considerable number of breast cancer patients no risk factor is found. 
Breast cancer is a heterogeneous disease, both genetically and clinically. Increased understanding of 
the histological, molecular, and functional divergence and characteristics of the disease formulates 
the classification standards of the various subtypes which impact diagnosis, prognosis, and 
treatment approaches (Turashvili & Brogi, 2017). Based on the site of the disease and whether it 
spreads beyond where it initially developed, breast cancer lesions are classified as invasive 
(infiltrating), which break through the wall of ducts and lobules and invade the surrounding tissues; 
and in situ carcinomas, which are local. The in situ carcinomas are further sub-classified into 
histologic subtypes including ductal carcinomas in situ (DCIS), which are confined to the ducts; and 
lobular carcinomas in situ (LCIS), which are found in the lobular epithelia and are much less 
common than DCIS. The histomorphological criteria classify invasive breast carcinomas into 
invasive ductal carcinomas (IDC), which comprise about 80% of all infiltrating breast cancers; 
invasive lobular carcinomas (ILC), which account for nearly 5–10% of cases; and other less 
common subtypes including medullar, tubular, papillary, and mucinous carcinoma (Makki, 2015). 
In active clinical practice, the most widespread classification of breast cancers is the tumor-node-
metastasis (TNM) staging system, which is based on tumor size, the number and location of 
involved lymph nodes, and the presence or absence of distant metastasis (Benson et al., 2003). 
Another decision-making factor in breast cancer treatment includes the grading system which 
assesses tubule formation, nuclear pleomorphism, and mitotic counts to indicate the overall tumor 
differentiation status: grade I is well-differentiated; grade II is moderately differentiated; and grade 
III is poorly differentiated (Elston & Ellis, 1991). To increase the accuracy of clinical decisions, it 
became necessary to incorporate molecular markers into the classification system and develop 
measurable prognostic and predictive markers. A prognostic marker is a clinical or biological factor 
which associates with the period of disease-free or overall survival regardless of therapy. A 
predictive marker is any measurable factor which associates with response or lack of response to a 
specific treatment (Clark, 2008). The conventional clinical biomarkers of breast cancers include ER 
(estrogen receptor), PR (progesterone receptor), and HER2/ERBB2/neu (human epidermal growth 
factor receptor 2), which are evaluated by immunohistochemical methods and classify the disease 
into basic therapeutic categories. Breast cancer cells which test positive for expression of ER and/or 
PR are classified as ER– and/or PR-positive. The majority of ER-positive breast cancers are also 
PR-positive, and together they account for roughly 65–75% of all breast cancer diagnoses. HER2 
positivity indicates the amplification and/or overexpression of HER2, commonly measured by 
immunohistochemistry, fluorescence in situ hybridization (FISH), or chromogenic in situ 
hybridization (CISH), and appear in almost 15–20% of primary breast cancers. Other clinically 
relevant breast cancer molecular markers include the immunohistochemical status of Ki67, a 
nuclear protein expressed in S, G1, G2, and M phases of the cell cycle but nonexistent in G0, which 
reflects the growth fraction of neoplastic cell population and thus is an index of high proliferation 
rate in primary tumors (Yerushalmi et al., 2010). Another clinical marker is the somatic mutation of 
TP53 which is found in 20–35% of human breast cancers. When missense mutated, TP53 
accumulates in the nucleus of malignant cells. The protein level can be assessed with 
immunohistochemical methods and might indicate the prognosis of the disease (Varna et al., 2011; 
Olivier et al., 2006; Abubakar et al., 2019). 
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Breast cancer tumors are also classified into further distinct intrinsic subtypes based on the presence 
or absence of ER/PR, overexpression of HER2, expression of cytokeratin (CK) 5/6 (index of basal 
cells), expression of CK8/18 (index of luminal cells), high level of Ki67, and TP53 mutation, and 
their gene expression profiling. The intrinsic subtypes of breast cancer based on their molecular 
classification and gene expression signature are as follows: 
(1) Luminal A-like, which is defined by ER/PR positivity, HER2 negativity, low expression of 
Ki67, expression of luminal associated markers including CK8 and 18, and comprises about 
50% of all invasive breast cancers. Luminal A-like cancers usually have a good prognosis 
and are typically of low grade. Their relapse rate is significantly lower than other subtypes 
and their treatment is mainly based on endocrine therapy (Masood, 2016; Perou et al., 2000; 
Coates et al., 2015).  
(2) Luminal B-like, which is ER/PR-positive, mostly HER2-positive, shows higher level of 
Ki67 compared to luminal A, and accounts for about 20% of invasive breast cancers. 
Luminal B-like breast cancers present a more aggressive phenotype and are of higher grade. 
The prognosis is poorer than luminal A and there is a higher recurrence rate and lower 
survival rate after relapse compared to luminal A. Their response to endocrine therapy and 
chemotherapy is variable (Masood, 2016; Perou et al., 2000; Coates et al., 2015).  
(3) HER2-positive, which strongly overexpresses HER2 and is negative for ER/PR or expresses 
lower ER levels. The HER2 subgroup also expresses a high level of Ki67 and is frequently 
TP53 mutated. The HER2-positive subtype accounts for 15% of all invasive breast cancer. 
HER2-positive cancers are more often of high grade and have lymph node metastasis, which 
implies poor prognosis, but they present the highest response to trastuzumab (Herceptin) 
therapy which significantly improves the prognosis (Masood, 2016; Perou et al., 2000; 
Coates et al., 2015; Albergaria et al., 2011).  
(4) The basal-like tumors comprise 8–37% of all breast cancers which express genes 
characteristic of the outer or basally located epithelial layer of the mammary gland, such as 
cytokeratins 5, 14, and 17 and the epidermal growth factor receptor (EGFR/HER1) and 
frequent mutation of TP53. Tha basal-like tumors that do not express ER and PR and do not 
overexpress HER2 are classified as triple negative breast cancer (TNBC). TNBCs are highly 
proliferative tumors which manifest high histological and nuclear grade and have a higher 
rate of metastasis (Masood, 2016; Cheang et al., 2015).  
(5) The normal-like subtype resembles the normal breast profiling and, similar to luminal A 
tumors, are ER/PR-positive, HER2-negative, and low Ki67. They express adipose and other 
nonepithelial genes and have high basal-like and low luminal gene expression. They usually 
show poor outcomes (Perou et al., 2000; Sorlie et al., 2001).   
It is important to clarify that the basal-like subtype, which is highly heterogeneous, is only used in 
research settings and not utilized in routine clinical practice (Yersal & Barutca, 2014; Cheang et al., 
2015). While daily clinical pathology practice applies the histologic type and grade, and 
immunohistochemical status of ER/PR/HER2 to determine the subtypes and consequently, the 




The breast cancer mortality rate has drastically decreased, largely owing to early detection of the 
disease through increased cancer awareness and advanced screening tests which include: 
mammography, which is an X-ray picture of the breast; magnetic resonance imaging (MRI), which 
produces high resolution pictures of the breast without the application of radiation; molecular breast 
imaging (MBI), which employs a radioactive tracer that lights up the cancer tissues in the breast; 
breast biopsy, which collects tissue samples to be analyzed by pathologists; immunohistochemistry 
assay, which uses antibodies to detect certain protein expression; and blood-based assays, which use 
breast biomarkers to detect cancer but due to its low sensitivity is only recommended in the 
metastatic settings. 
 
2.2.3 Breast cancer treatment 
2.2.3.1 Predictive factors  
Despite the increasing rate of breast cancer incidence, early detection and advances in therapy have 
improved the patients’ survival rates. The decline of breast cancer mortality is attributable to 
reliable and clinically applicable predictive factors, which aid in choosing the treatment that is most 
likely to benefit individuals, as well as the improved adjuvant therapies after initial surgery. ER is a 
strong predictive marker which is commonly used to select patients who would benefit from 
endocrine therapy. In addition to ER, the PR measurement is considered to improve prediction of 
endocrine therapy response. Another strong predictive factor of breast cancer treatment response is 
HER2, which identifies patients who benefit from anti-HER2 therapy (Cao et al., 2016). The impact 
of ER, PR, and HER2 and their relation to breast cancer treatment is further described in the 
following section. The Ki67 protein expression, which is an index of proliferation rate and a 
somewhat common prognostic factor, has also been discussed to provide prediction potentials for 
chemotherapy response (Dowsett, et al., 2011). Further, the germline mutations in BRCA1 or 
BRCA2 represent promising predictive factors for PARP inhibitors for cancer therapy. However, the 
decision of which treatment to use might also be influenced by additional factors such as the stage 
and HER2 status of the cancer, as well as the status of other homologous recombination genes 
(Ohmoto, et al. 2017; Robson, et al. 2017). 
 
2.2.3.2 Treatment 
Most breast cancer patients have surgery to remove localized cancer. After the sentinel lymph node 
biopsy, patients with confirmed positive status undergo the removal of lymph node during surgery. 
The Types of surgery include breast-conserving surgery, total mastectomy, and modified radical 
mastectomy. However, modified radical mastectomy is a historical standard of management, which 
is withheld in the present day and used only for select patients. Surgery, radiation therapy, and 
systemic treatment, comprise the main care plan currently applied to treat breast cancer patients.  
Radiation therapy decreases the risk of recurrent breast cancer by 16% (19% vs 35%) and the risk of 
mortality due to breast cancer by 4% (21% vs 25%) (Buchholz, 2011). While radiation therapy 
improves patients’ survival, there is also evidence of dose-driven late complications, including the 
risk of late cardiac toxicity (Darby et al., 2013).  
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Systemic treatment of breast cancer includes cytotoxic, hormonal, and immunotherapeutic agents 
which are administered in neoadjuvant (i.e. preoperative), adjuvant (i.e. postoperative), and 
metastatic settings. Breast cancer subtype and anatomic cancer stage determine the standard 
systemic therapy administered which, in combination with patient preference, make for the optimal 
therapy.  
Adjuvant chemotherapy, mostly administered as a combination treatment, reduces the risk of 
recurrent disease in early-stage breast cancer (Blum et al., 2017). Primary chemotherapy consists of 
regimens that may include non-anthracycline (containing combinations such as cyclophosphamide, 
methotrexate, and 5-fluorouracil (CMF)); anthracycline (in combination with other agents such as 
5-fluorouracil, and cyclophosphamide (FAC)), cyclophosphamide and 5-fluorouracil (CAF), and 
cyclophosphamide (AC); taxane-based therapy (such as paclitaxel and docetaxel); and anthracycline 
and taxane combinations. Chemotherapy decreases the 10 year risk of death due to breast cancer by 
between 7% and 33% (Early Breast Cancer Trialists' Collaborative Group (EBCTCG), 2012, 2018; 
Schmidt, 2014). However, the major challenges ahead in the field of cancer therapy include: 
toxicities including (but not restricted to) immunosuppression, asthenia (fatigue), edema (swelling), 
and myalgias (muscle aches) (Tao, Visvanathan & Wolff, 2015); and the multiple pathways of 
resistance involved, i.e. while the first line of chemotherapy in metastatic or advanced disease is 
usually efficient, the vast majority of patients inevitably develop drug resistance in subsequent 
treatments (Gonzalez-Angulo, Morales-Vasquez & Hortobagyi, 2007).  
In addition to chemotherapy, two hallmark events have drastically increased the breast cancer 
survival rate. First was the identification of endocrine hormonal therapy for ER/PR-positive patients 
in the 1980s, and second was the approval of HER2-direct monoclonal antibodies (trastuzumab) in 
treating HER2-positive patients in the 1990s. Endocrine therapy is a central component of both 
adjuvant and metastatic treatment for ER-positive patients. The ER and PR content of breast cancer 
cells are highly correlated with patient responses to hormonal therapy. Categorically, the non-
metastatic patients with ER and/or PR positivity and HER2 negativity, which comprise almost 70% 
of breast cancer cases, receive five (to 10) years of oral endocrine treatment as their primary 
systemic therapy. Common endocrine therapies include tamoxifen, an antiestrogen medication 
effective in both pre– and postmenopausal patients; and aromatase inhibitors, which are effective 
only in post-menopausal patients (Waks & Winer, 2019). While the absolute benefit of tamoxifen is 
proportionate to the risk attributed to a given tumor, overall, ER-positive patients who are treated 
with five years of adjuvant tamoxifen experience at least a one third reduction of the risk of 15-year 
mortality due to breast cancer (Early Breast Cancer Trialists' Collaborative Group (EBCTCG), 
2011). Aromatase inhibitors appear to benefit patients’ survival even more than tamoxifen; five 
years of aromatase decreases 10-year mortality due to breast cancer by approximately 15% 
compared with tamoxifen — thus, by about 40% (proportionally) compared with no hormonal 
treatment (Early Breast Cancer Trialists' Collaborative Group (EBCTCG), 2015). In endocrine 
therapy, similar to other cancer therapies, toxicity concerns may lead to suboptimal treatment. The 
common (>10%) toxicities associated with endocrine therapy include hot flashes, arthralgias or 
myalgias (BIG 1-98 Collaborative Group et al., 2009). 
In some hormone receptor-positive patients, chemotherapy and endocrine therapy are administered 
sequentially to achieve the optimal treatment. However, the clinician’s decision on if and when to 
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add chemotherapy is based on clinicopathological features (which are not sufficient to assess the 
chemosensitivity), and at times the two gene expression signature assays (Harris et al., 2016; Krop 
et al., 2017) which are recommended by the American Society of Clinical Oncology — but not 
universally accepted due to early stage data. Therefore, the therapy combination that works best for 
patients, especially in node-positive disease, is somewhat defined through trial and error, which 
challenges the principal of avoiding overtreatment and undertreatment of patients. 
The discovery and FDA approval of HER2-targeted therapy in the 1990s has been one of the 
greatest advances in breast cancer treatment. All confirmed HER2-positive patients, unless 
clinically inappropriate, receive HER2-targeted therapy such as trastuzumab, lapatinib, pertuzumab, 
and T-DM1. HER2-targeted therapy, typically in conjunction with chemotherapy, has dramatically 
increased the disease-free survival and overall survival rate of HER2-positive patients (Fisher et al., 
1989; Slamon et al., 2001). Further, it has been shown that adding one year of trastuzumab to 
standard adjuvant chemotherapy, particularly docetaxel and carboplatin, increases disease-free 
survival and overall survival in patients with HER2 positivity (Slamon et al., 2011). The most 
notable, but not the most common, therapy complication associated with trastuzumab includes 
cardiotoxicity (Mohan et al., 2018). Ongoing investigations aim to reduce the duration of treatment 
and decrease the number of accompanying chemotherapy agents in lower risk patients in order to 
limit toxicities, as well as to discover novel agents to treat higher risk patients more effectively. 
Perhaps the most challenging class of breast cancer to treat is the triple negative subtype, which has 
an aggressive clinical course and, due to the lack of established targeted therapy, virtually all triple 
negative patients receive chemotherapy. The 2017 result of the CREATE-X trial favored the 
administration of post-neoadjuvant fluorouracil-based drug capecitabine to improve patients’ five-
year disease-free survival by about 7%. However, due to early stage data and non-negligible 
toxicities, the integration of capecitabin into clinical treatment requires further examination 
(Masuda et al., 2017). Also, it has been suggested that adding carboplatin to a neoadjuvant 
chemotherapy regimen might marginally improve patients’ disease-free survival in addition to an 
improved pathologic complete response at surgery (Masuda et al., 2017; Loibl et al., 2018). 
However, the role of a platinum-based agent in treating triple negative patients remains to be 
evaluated. One of the most promising therapeutic agents for breast cancer with BRCA1 and BRCA2 
mutation or other homologous recombination deficiency is the PARP inhibitor, which functions 
based on the fact that PARP inhibition is lethal for BRCA1/2 deficient cells (Keung, Wu & 
Vadgama, 2019).  
Finally, while the principles of systemic therapy are the same for both non-metastatic and metastatic 
patients, the therapeutic goals and extent of therapy might be slightly different between the two 
groups. Generally, in non-metastatic patients the aim of therapy is to eliminate tumor from the 
breast and surrounding lymph nodes, eradicate possible systemic spread of the disease and prevent 
metastatic recurrence, whereas in metastatic patients, the goal is to prolong life and alleviate 
symptoms (Waks & Winer, 2019). 
While advances in diagnosis and treatment of breast cancer have decreased the mortality rate in 
high-income countries, patients in low-income countries bear a higher burden of cancer death and 
the difference is especially pronounced in women with younger age of onset (Bellanger et al., 
2018). Therefore, to reduce breast cancer mortality worldwide, it is important to secure the 
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availability of early stage diagnostic methods to detect the cancer at a surgically removable stage, 
and to ensure patients’ access to effective adjuvant treatment. 
 
2.3 Genetic predisposition to breast cancer 
Similar to most cancers, the majority of breast cancer cases arise from somatic mutation and thus 
are sporadic. However, family aggregation and epidemiological evidence indicate the role of 
hereditary factors in breast cancer development. The heritable component accounts for 
approximately 10% of all breast cancer (Easton, 2002). Population-based case control studies report 
that a family history of breast cancer and early age of onset (<40 years old) associate with increased 
risk of developing breast cancer. The 1.4-fold relative risk of women older than 60 years with a 
breast cancer relative diagnosed after age of 60 increases to five-fold relative risk in women 
younger than 40 years with breast cancer relatives diagnosed before age of 40 (Easton, 2002). The 
proportion also increases with the number of affected relatives, i.e. compared to women with no 
breast cancer family history, the reported risk ratio associated with one, two, and three or more 
affected relatives is 1.8, 2.93, and 3.9, respectively (Collaborative Group on Hormonal Factors in 
Breast Cancer, 2001a). In principal, observed family aggregation of breast cancer could arise from 
both genetic and non-genetic components, given that family members probably share a somewhat 
similar environment, but the discovery of BRCA1/2 germline mutations and twin studies indicate 
the impact of hereditary factors to be substantial (Michailidou et al., 2013; Lichtenstein et al., 
2000).  
Breast cancer in males is rare, accounting for less than 1% of all breast cancer cases. Overall, the 
lifetime risk of breast cancer in men is 1:1000 compared to 1:8 for women. However, the risk is 
increased two-fold for men with a first-degree breast cancer relative, indicating that the impact of 
heritable components is significant (Giordano, 2018). 
Historically, in pursuit of breast cancer susceptibility genes, investigators applied three main 
methods: linkage analysis, screening of candidate genes, and genome-wide analysis study. Each 
method is best suited to discover a certain class of breast cancer susceptibility variants — that is 
high–, moderate–, and low-penetrance susceptibility variations, respectively — based on their allele 
frequency and penetrance. In general, the susceptibility alleles conferring lifetime breast cancer risk 
of >50%, >20% and >10% are broadly categorized as high–, moderate–, and low-penetrance 
predisposing variations (Ghoussaini, Pharoah & Easton, 2013). There is an adverse correlation 
between the allele frequency of the cancer predisposing variants and their penetrance, i.e., the high-
penetrance cancer susceptibility variants have lower allele frequency in general population (Figure 
3). The correlation is intuitively apparent, as the strong inherited predisposition to cancer is not 





Figure 3. Source: National Cancer Institute: The general findings indicate the adverse association between 
the allele frequency and the penetrance of cancer predisposing variants. 
 
High-risk families with breast cancer are typified by multiple cases with early onset (<50 years old), 
high rate of bilateral breast tumors, ovarian cancer, and the presence of male breast cancer cases. 
Nonetheless, one of the major difficulties in discovering germline cancer variants is that it can be 
challenging to unambiguously define the familial breast cancer cases. The reasons include the high 
breast cancer incidence rate in general population and the fact that sporadic breast cancer, too, can 
present as bilateral and occur prior to menopause. Therefore, rigorous methods of epidemiology and 
genetic analysis are essential for unfolding the hereditary basis of breast cancer. 
 
2.3.1 High-penetrance breast cancer susceptibility genes 
Using pedigree-segregating data, breast cancer studies applied linkage analysis to discover the high-
risk breast cancer predisposing genes. BRCA1 and BRCA2 are the most important high-penetrance 
breast cancer genes. Additionally, mutations in high-risk cancer genes such as TP53, PTEN, 
STK11/LKB1, CDH1 and NF1 result in pleiotropic tumor syndromes including the cancerous 
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tumor(s) of the breast. The following subsections briefly discuss the high-risk breast cancer genes 
involved in hereditary cancer predisposition. 
 
2.3.1.1 BRCA1 and BRCA2  
In 1990, Mary-Claire King and her colleagues established linkage of early onset familial breast 
cancer cases to the long arm of chromosome 17 (Hall et al., 1990), which by 1994, led to the 
mapping and cloning of BRCA1 and the identification of BRCA1 truncating mutations in families 
with multiple breast cancer cases (Miki et al., 1994). The BRCA1 discovery was followed by 
mapping and positional cloning of the second breast cancer susceptibility gene, BRCA2, in 1995 
(Wooster et al., 1995). BRCA1 and BRCA2 are caretaker tumor suppressors involved in DNA 
repair mainly by activating the repair of double-strand breaks and initiating homologous 
recombination DNA repair. BRCA1/2 mutations are evenly distributed along the coding sequence of 
the genes. The germline mutations in BRCA1/2 are often truncations of the open reading frame 
caused by small insertions and deletions, nonsense mutations, and splice site alterations. BRCA1/2 
deficiency increases the genome instability and hypersensitivity to crosslinking events and agents, 
which produce double-strand breaks, and therefore, confer increased risk of cancer development.  
Women carrying BRCA1 or BRCA2 mutations have a 57–65% or 45–55% risk for breast cancer by 
age 70, and a 39–44% or 11–18% lifetime risk of developing ovarian cancer, respectively 
(Antoniou et al., 2003, Chen, Parmigiani, 2007, Mavaddat et al., 2013). However, the pattern of 
cancer, as well as the estimated risk and prevalence conferred by BRCA1/2 mutations, can vary 
between families, sample sets, and populations, possibly due to other modifying genes and 
components of family history, sample selection, and the environment. BRCA1/2 mutations also 
increase the risk of developing Fallopian tube, colon, melanoma, and pancreas cancer (van der 
Groep, van der Wall & van Diest, 2011a). Men with mutations in BRCA1 and BRCA2 are at 
increased risk of developing breast cancer by 1.2% and 6.8%, respectively (Tai et al., 2007). 
BRCA1 mutations account for 0–4% and BRCA2 mutations account for 4–16% of all male breast 
cancer cases (Giordano, 2018). BRCA1 and, particularly, BRCA2 mutations in men also increase the 
risk of prostate cancer (van der Groep, van der Wall & van Diest, 2011b). However, about one third 
of male breast cancer cases without a known BRCA1/2 mutation have a relative (male or female) 
with breast cancer, suggesting the possible involvement of additional genetic factors. 
BRCA1/2-related breast cancer distribution of histopathological characteristics differs from that of 
other breast cancers. Both BRCA1– and BRCA2-related breast cancers are usually of high grade, but 
BRCA1-related tumors are more often grade 3 than BRCA2-related tumors. BRCA1 cancers are 
usually triple negative basal-like subtypes, whereas BRCA2 cancers are commonly hormone 
receptor positive. Also, BRCA1 mutations often associate with medullary breast cancer tumors 
(Spurdle et al., 2014). Despite featuring the tumor characteristics associated with poor prognosis, 
studies do not provide conclusive results for poorer survival of BRCA1/2 carriers compared to non-
carriers (van den Broek et al., 2015), partially due to the relatively small sample size of the studies 
(because similar to other high-penetrance cancer genes, BRCA1/2 mutations are rare in general 
population). BRCA1 and BRCA2 mutation frequency in general breast cancer patients unselected for 
family history, age of onset or other hallmarks of high-risk groups are as low as 0–7% and 1.1–
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2.6%, respectively (Fackenthal & Olopade, 2007). An exception to the low frequency of BRCA1/2 
mutations in general population is the Ashkenazi Jewish population, in which the three main BRCA-
founder mutations are very common (van der Groep, van der Wall & van Diest, 2011b). 
 
2.3.1.2 Cancer predisposition syndromes  
Some hereditary breast cancers are caused by other rare dominant autosomal hereditary syndromes 
such as Li-Fraumeni syndrome, Cowden syndrome and Peutz-Jeghers syndrome, which are 
associated with mutations in TP53, PTEN (phosphatase and tensin homolog), and SKT11/LKB1 
(liver kinase B1), respectively.  
Li-Fraumeni syndrome is typified by familial clustering of early onset bone or soft tissue sarcomas, 
leukemias, and by increased risk of other carcinomas including those of the breast. TP53 germline 
mutations are present in nearly 70% of families meeting the diagnostic criteria of Li-Fraumeni 
syndrome. The majority of mutations are missense, causing the synthesis of an abnormal TP53 
mutant protein and subsequently the TP53 dominant negative effect (Malkin et al., 1990). The 
cumulative cancer risk in individuals carrying germline TP53 mutation is high, with nearly 100% 
penetrance over carriers’ lifetimes, and with females aged over 20 years having a higher risk than 
males due to breast cancer. Breast cancer accounts for 26.4% of all cancer diagnosis within Li-
Fraumeni families, with 58% of them occurring before age 50; however Li-Fraumeni syndrome 
accounts for less than 1% of all breast cancer cases (Wooster & Weber, 2003). Female carriers have 
a 54% cumulative risk of breast cancer by age 70 (Mai et al., 2016; Amadou, Waddington Achatz & 
Hainaut, 2018). The role of TP53 mutation in breast cancer will be further discussed in section 2.5. 
Cowden syndrome, also known as multiple hamartoma syndrome, is another rare autosomal 
dominant hereditary cancer syndrome with an increased risk of breast cancer (Hobert & Eng, 2009). 
In addition to hamartomatous polyposis, Cowden syndrome also associates with pathognomonic 
physical features such as macrocephaly, delayed development, and oral papillomatous papules 
(Eng, 2000). Cowden syndrome is caused by a germline inactivating mutation in PTEN, which 
functions as a gatekeeper tumor suppressor through cell cycle arrest or apoptosis — or both — and 
plays a key role in inhibition of the oncogenic AKT/PI3K signaling pathway. Germline PTEN 
mutations also increase the risk of melanoma, thyroid, endometrium, colorectum and kidney 
cancers (Tan et al., 2012). Cowden syndrome female patients bear an elevated lifetime risk of 
developing breast cancer by 25–50% (Thull & Vogel, 2004) and an even higher risk (85%) was 
estimated in another study (Tan et al., 2012). Breast cancer in Cowden syndrome patients occurs in 
young age, starting at 30 years and commonly found between ages 38 and 46 (Hobert & Eng, 2009). 
Male breast cancer has also been suggested to associate with Cowden syndrome (Fackenthal et al., 
2001). 
Another rare autosomal dominant hamartomatous condition that significantly elevates the risk of 
breast cancer is Peutz-Jeghers syndrome. This syndrome is characterized by the development of 
benign hamartomas along the gastrointestinal tract and pigmented macules on the lips, fingers, toes 
and oral mucosae (Hemminki et al., 1998; Beggs et al., 2010; de Leng et al., 2007). Germline 
mutations in the STK11/LKB1 gene are detected in 80–94% of affected families. STK11/LKB1 is a 
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tumor suppressor gatekeeper which is involved in cell cycle regulation. Patients with Peutz-Jegher 
syndrome are at an elevated risk of developing gastrointestinal and various non-gastrointestinal 
malignancies. The most commonly reported malignancies are colorectal cancer with a lifetime risk 
of 39%, followed by breast cancer with a risk of 31–54% by age 64 (Hearle et al., 2006; Giardiello 
et al., 2000). 
CDH1 (cadherin-1) gene is another rare high-risk cancer gene in which the germline mutation also 
associated with elevated risk of hereditary lobular breast cancer. CDH1 encodes for the E-cadherin 
protein, which is a transmembrane glycoprotein expressed in epithelial tissues and is involved in 
cell-to-cell adhesion and functions as a cell invasion suppressor. Aberrant E-cadherin compromises 
cell adhesion and increases cell motility and metastatic ability of the tumors (Corso et al., 2016). 
Mutations in CDH1 associate with familial diffuse gastric cancer, an autosomal dominant cancer 
syndrome, and predispose affected females to lobular breast carcinoma. For CDH1 mutation 
carriers, the risk of developing lobular breast cancer is 42% by age 80 (Hansford et al., 2015). 
Germline alteration in NF1 (neurofibromin 1) causes neurofibromatosis, which is characterized by 
multiple benign lesions. Patients affected by neurofibromatosis develop cancer at an elevated risk 
compared to the general population. Compared to other autosomal dominant malignancies discussed 
here, neurofibromatosis is the most common with a prevalence of 1/3500 (Frayling et al., 2019). 
Suggestive evidence indicates that women with neurofibromatosis have a five-fold increased risk of 
breast cancer manifested with more advanced forms of the disease (Suarez-Kelly et al., 2019; 
Easton et al., 2015). 
 
2.3.2 Moderate-penetrance breast cancer susceptibility genes  
Breast cancer investigators have identified moderate-risk genes mainly through resequencing of 
candidate genes. Also, recent developments in exome and whole genome sequencing have reduced, 
at least, the technical limitation of candidate gene studies and contributed to establishing novel 
moderate-risk breast cancer genes. Genes such as PALB2, CHEK2 and ATM are among the well-
studied moderate-penetrance breast cancer susceptibility genes. 
PALB2 (partner and localizer of BRCA2), also known as FANCN, is a BRCA2 interacting factor 
and a linker protein between BRCA1 and BRCA2 (Xia et al., 2006), which plays a key role in DNA 
damage response through homologous recombination and the Fanconi anemia pathway 
(Nepomuceno et al., 2017). Bi-allelic germline loss-of-function in PALB2 accounts for a subset of 
Fanconi anemia cases, whereas monoallelic loss-of-function contributes to increased breast cancer 
risk. Studies report that PALB2 c.1592delT, a frameshift founder mutation in Finland which is 
present in almost 1% of breast cancer women unselected for familial history, confers a nearly six-
fold increased risk of breast cancer; possibly this is due to compromising its BRCA2-binding 
capacity (Erkko et al., 2007). The absolute breast cancer risk for PALB2 mutation carriers by 70 
years of age and with no familial history is 33%, compared to the absolute risk of 58% in carriers 
with two or more first-degree breast cancer relatives at 50 years of age (Antoniou et al., 2014). 
Studies also suggest that PALB2 mutations may increase the risk of male breast cancer (Antoniou et 
al., 2014; Blanco et al., 2012). 
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CHEK2 (checkpoint kinase 2) encodes for a serine/threonine kinase which has a key role in DNA 
repair, cell cycle regulation, and apoptosis in response to DNA damage. CHEK2 is activated 
through the phosphorylation of the Thr68 site by ATM (following DNA damage) or PRKDC 
(during normal mitosis) leading to its interaction with downstream substrates of apoptosis 
(including TP53 MDM2), DNA repair (including BRCA1 and PML), and components of mitotic 
spindle assembly (including BRCA1) (Magni et al., 2014; Kastan, & Bartek, 2004; Shang et al., 
2014). A truncating mutation CHEK2 c.1100delC associates with elevated risk of breast cancer. The 
estimate is slightly elevated for carriers with history of familial breast cancer (Schmidt et al., 2016; 
Nevanlinna & Bartek, 2006): a meta-analysis of 42 studies reported the aggregated odds ratio of 2.7 
for unselected breast cancer versus the odds ratio of 4.8 for familial cases (Weischer et al., 2008). 
Another study summarized the estimated risk for carriers with no affected relative to be 20%, and 
for carriers with familial history to be 44% (Apostolou & Papasotiriou, 2017). An investigation of 
CHEK2 c.1100delC in over 86,000 individuals in Copenhagen general population showed 
association also with other cancers, including those of the stomach, kidney, sarcoma and prostate 
(Naslund-Koch, Nordestgaard & Bojesen, 2016). 
The ATM (ataxia telangiectasia mutated) gene encodes for a checkpoint kinase which is involved in 
the initiation of double-strand break repair through homologous recombination. Bi-allelic mutation 
of ATM associates with the rare autosomal recessive condition known as ataxia telangiectasia (AT) 
(Savitsky et al., 1995). AT is characterized by cerebellar ataxia, immunodeficiency, and elevated 
risk of cancer, especially leukemia and lymphoma. The heterozygous mutation of ATM does not 
cause AT but the carriers have a two– to three-fold elevated risk of developing breast cancer 
(Renwick et al., 2006; Thompson et al., 2005). This is an increased lifetime relative risk of 25% 
compared to the general population (Jerzak, Mancuso & Eisen, 2018). 
Studies have suggested several other genes which are highly involved in homologous recombination 
repair of double-strand breaks as moderate-penetrance. The most notable genes include BRIP1, 
RAD51C and RAD51D, which mainly associate with ovarian cancer but may also impact breast 
cancer risk; however, their precise contribution to increased risk of breast cancer remains to be 
further investigated (Weber-Lassalle et al., 2018; Norquist et al., 2016; Pelttari et al., 2011). A 
series of other DNA repair genes — namely, NBN (Zhang et al., 2013), MRE11A (Bartkova et al., 
2008), XRCC2 (Park et al., 2012), FANCM (Kiiski et al., 2014), and FANCC (Thompson et al., 
2012) — have been proposed to associate with breast cancer risk, however, the exact penetrance 
attributable to these genes is yet to be established (Easton et al., 2015). Table 1 summarizes the 









Table 1. High– and moderate-penetrance breast cancer predisposition genes and the predominant cancer 
susceptibility. 
Gene Cancer syndrome Cancer  Estimated penetrance 
BRCA1 Familial breast and ovarian 
cancer 
Breast, Ovarian  55-65% breast, 40% ovarian 
BRCA2 Familial breast cancer Breast  45% breast, <20% ovarian 
TP53 Li-Fraumeni syndrome Breast, Sarcoma 90% (breast, females) 
PTEN Cowden syndrome Breast, Thyroid, Endometrial  85% (breast) 
STK11/LKB1 Peutz-Jegher syndrome Breast 31-54% (breast) 
CDH1 Familial diffuse gastric cancer Breast, Gastric 42% (breast) 
NF1 Neurofibromatosis type 1 Brain, Neural tumors, Breast >95% develop benign lesions, 
5% develop cancer 
PALB2 Fanconi anemia Breast 33-58% 
CHEK2 Checkpoint kinase 2 Breast, Stomach 20-44% (breast) 
ATM Ataxia telangiectasia Breast, Lymphoma 25% (breast) 
 
2.3.3 Low-penetrance breast cancer susceptibility genes  
Rare germline mutations in known high– and moderate-penetrance genes explain only 25% of 
familial risk and less than 5% of all breast cancer predisposition (Thompson & Easton, 2004). 
Family members usually share a similar environment, but the environmental factor is unlikely to 
explain all familial clustering of the disease. It is possible that it is partially attributable to the 
combination of common variants, each conferring a small breast cancer risk (Ghoussaini, Pharoah 
& Easton, 2013). Furthermore, twin studies have shown that the concordance for cancer is higher in 
monozygotic twins compared to dizygotic twins. For instance, one of the largest twin studies 
estimated a 5.2 relative risk of breast cancer for monozygotic twins compared to 2.8 in dizygotic 
twins (Lichtenstein et al., 2000). The higher cancer risk in monozygotic twins not only suggests that 
the genetic factor might be more important than the environmental factor, but also supports the 
hypothesis of breast cancer being a polygenic disease. Thus, the higher risk in monozygotic twins 
and the familial aggregation of breast cancer could also conceivably result from the cumulative 
impact of multiple low-penetrance alleles (Antoniou & Easton, 2006).  
GWAS (genome-wide association studies) have identified the majority of low-risk common 
variants in breast cancer. The GWAS method is based on a tagging approach which scans markers, 
i.e. SNPs (single-nucleotide polymorphism) or CNVs (copy number variation), across the genome 
which are in linkage disequilibrium with each other. Owing to the linkage disequilibrium structure, 
the tagging SNPs represent similar information and impact as SNPs in the same haplotype block. 
However, this also means that the representative SNP may not necessarily be the causal variant. 
Detecting the causal variant is the most challenging part of GWAS, especially when the tagging 
SNPs reside in gene deserts. The identification and estimation of the causative variant is usually 
approached with methods of fine-mapping of the risk locus, phenotype prediction, heritability 
estimation, and functional annotation of pathway analysis (Easton et al., 2007). Many of these 
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variants are likely to play the regulatory role by modulating the expression of target genes 
(Michailidou et al., 2017). The power to discover common predisposing small size-effect variants 
largely depends on the sample size of both discovery population and the validation sets, which 
became possible through international consortia such as BCAC (Breast Cancer Association 
Consortium) (Broeks et al., 2011). Overall, common predisposing variants discovered by GWAS 
account for 18% of breast cancer genetic background (Michailidou et al., 2017). While individual 
susceptibility SNPs discovered by GWAS confer only a small risk, the combined effect as a 
polygenic risk score (PRS) is significant (Mavaddat et al., 2015). 
Because of the small size effect, the predictive competence of low-risk SNPs for individuals is 
limited. However, an examination of population-based breast cancer cases to evaluate the potential 
of breast cancer risk prediction through common variants suggested that the power of common risk 
variables is useful for distinguishing between high– and low-risk groups (Pharoah et al., 2002, 
2008). A study of 33,673 cases and 33,382 control women of European origin estimated the risk 
stratification ability of PRS of 77 breast cancer-associated SNPs: the study found that women in the 
highest and lowest 1% of the PRS bear a 29% and 3.5% risk of developing breast cancer by age 80 
(Mavaddat et al., 2015) compared to women in the middle quantile (40th to 60th percentile). A recent 
large-scale case control study by the same researchers found that for the breast cancer PRS based on 
313 SNPs, the lifetime risk of breast cancer among women in the highest 1% of the distribution is 
four-fold greater than those in the middle quantile. They also attempted to optimize PRSs for 
subtype-specific disease, and reported that women in the highest 1% of risk had 4.37– and 2.78-fold 
risks, and those in the lowest 1% of risk had 0.16– and 0.27-fold risks of ER-positive and ER-
negative breast cancer, respectively, compared to women in the middle quantile. Interestingly, the 
predictive performance of the 313-SNP PRS significantly improved over their previous report of 
77-SNP PRS, suggesting that the PRS based on low-risk SNP may offer powerful risk 
discrimination. However, the optimal assessment of risk discrimination requires the combination of 
PRS with family history, genetics, age, and other established risk factors (Mavaddat et al., 2019). 
 
2.4 Genetics of breast cancer survival 
Several factors — including, age, tumor stage, tumor subtype, drug sensitivity, and metastasis — 
may affect the likelihood of survival and indicated treatment in breast cancer patients (Goldhirsch et 
al., 2001; Pritchard et al., 2006). The TNM staging of the tumor strongly predicts breast cancer 
prognosis. Additionally, germline alterations might influence the age of onset, efficacy of adjuvant 
treatment, and the risk of certain tumor subtypes that are associated with the prognosis of the 
disease. Several studies investigated the association of the inherited component in characteristics 
and prognosis of breast cancer, and the molecular mechanism behind it.  
Large Swedish population-based studies indicated that good and bad prognosis in breast cancer 
aggregate within families, which suggests the existence of a familial factor in patients’ survival 
(Hemminki et al., 2008; Lindstrom et al., 2007; Hartman et al., 2007; Verkooijen et al., 2012) which 
could be largely distinct from familial risk (Hemminki et al., 2008). A breast cancer cohort study 
including 2,787 mother–daughter pairs and 831 sister pairs reported that first-degree relatives of a 
patient with a poor prognosis had a 60% higher breast cancer death rate compared to those of a 
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patient with a good prognosis, with a hazard ratio of 1.6 for daughters and 1.8 for sisters (Hartman 
et al., 2007). Children of parents with poor survival showed an increased hazard ratio of 1.7 for 
breast cancer death compared to those with good parental survival (Lindstrom et al., 2007). An 
additional population-based cohort study by Lindstrom et al., which included 1,617 sister pairs 
(almost twice as many as the previous study) (Hartman et al., 2007), found a two– to three-fold 
increased hazard ratio, adjusted for tumor characteristics and treatment, for breast cancer death in 
younger sisters with poor older sister survival compared to those with good sister survival 
(Lindstrom et al., 2014). 
Although BRCA1/2 genes were implicated as risk factors, their high penetrance and major 
functional role in DNA damage response pathways made them usual suspects also for survival 
studies. Breast cancer patients diagnosed under 50 years of age with BRCA1/2 mutation are prone to 
unfavorable outcomes (Schmidt et al., 2017). However, the results of accumulated individual 
studies investigating the effect of BRCA1/2 on patients’ survival have been inconclusive, but tend to 
point to a lack of large impact (van den Broek et al., 2015; Verkooijen et al., 2006). The prevalence 
of BRCA1/2 mutations is low, which results in limited statistical power for detecting the magnitude 
of their prognostic effect (Lee et al., 2010). Yet in a meta-analysis of 13 breast cancer survival 
studies, BRCA1 associated with poor overall survival (HR = 1.50, 95% CI = 1.11–2.04) compared 
to non-carriers, but BRCA2 mutations did not influence the likelihood of survival (Zhong et al., 
2015). Among other rare high– and moderate-risk breast cancer genes, germline mutation in PTEN 
(Heikkinen et al., 2011), PALB2 (Heikkinen et al., 2009), and CHEK2 (Weischer et al., 2012) 
appeared to affect breast cancer progression and patients’ survival. However, similar to with 
BRCA1/2, the low frequency of mutations make survival analyses challenging. 
Many individual studies have reported the association between common germline variations in 
candidate genes and breast cancer survival (Azzato et al., 2008; Fasching et al., 2008; Ambrosone et 
al., 2005), but there has been little success in conclusively replicating them. It is noteworthy that 
statistical power, particularly the number of death events, plays a critical role in survival analysis 
and limits the detection power to variations conferring higher hazard ratios which are not likely to 
exist after all. Thus, a GWAS-based survival analysis with a modest sample size is often 
unsuccessful in consistently detecting prognostic alleles (Azzato et al., 2010a, 2010b). Recently, 
few large meta-analyses, which pooled genotype data from multiple breast cancer GWAS in 
populations of European ancestry attempted to identify common variants associated with breast 
cancer-specific survival. Guo et al. discovered a novel locus (rs2059614 at 11q24.2) associating 
with poor survival in breast cancer patients with ER-negative tumors (HR = 1.95, 95% CI = 1.55–
2.47) (Guo et al., 2015). Another study by Khan et al. discovered two new loci (rs992531 at 8p21.2 
and rs7701292 at 5q21.3) which associated with decreased survival among ER-positive patients 
(HR = 1.85) and endocrine-treated patients (HR = 1.79), respectively. Additionally, they conducted 
an interaction analysis which implicated that the survival association of rs7701292 is treatment-
specific and independent of conventional prognostic markers (per-allele HRrs7701292: endocrine 1.92) 
(Khan et al., 2017). 
The impact of heritable components on treatment outcome is less understood. Several studies have 
shown that genetic variations may influence treatment efficacy, which consequently influence 
breast cancer survival after diagnosis (Fagerholm et al., 2008; Schroth et al., 2007; Seibold et al., 
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2013). There are also reports on the implications of SNPs in predicting therapy-related toxicity 
(Palmirotta et al., 2018). Kiyotani et al. conducted a Japanese GWAS analysis on 462 ER-positive 
breast cancer patients, including 240 study subjects and two independent sets of 105 and 117 cases 
of validation sets. The study identified rs10509373 in C10orf11 gene which associated with 
recurrence-free survival in patients receiving adjuvant tamoxifen therapy (Kiyotani et al., 2012). 
Moreover, a two-study GWAS analysis found locus 19q13.41 represented by rs8113308 to 
associate with 10-year breast cancer survival after endocrine therapy, and proposed that patients 
carrying rs8113308 rare allele may not benefit from adjuvant endocrine treatment (Khan et al., 
2015). Two other SNPs, i.e. rs6500843 and rs11155012, were also reported to associate with breast 
cancer survival in patients treated with chemotherapy, with rs6500843 specifically interacting with 
chemotherapy independent of other conventional prognostic markers, and rs11155012 specifically 
associating with anthracycline treatment (Fagerholm et al., 2015). Also, a homozygous missense 
variant, rs1800566, in oxidative stress response gene NQO1 predicts poor survival among breast 
cancer patients, particularly after anthracycline-based adjuvant chemotherapy (Fagerholm et al., 
2008). The role of NQO1 protein expression in breast cancer prognosis will be further discussed in 
sections 2.7 and 5.3. 
2.5 TP53 
TP53 associates with almost every type of human cancer and is the first gene described as a breast 
cancer gene. The implication of TP53 somatic mutation in mammary carcinogenesis is evidenced 
by its high frequency in breast cancer (Nik-Zainal et al., 2019). The germline mutation in TP53, as 
mentioned in subsection 2.3.1.2, causes Li-Fraumeni syndrome: a familial cancer disorder. Women 
carrying germline mutation in TP53 have a very high risk, up to 90%, of developing breast cancer. 
The risk conferred by TP53 germline mutation is even higher than BRCA1 and BRCA2 mutations, 
but it is much rarer in the population.  
Several studies have shown germline mutation in patients with familial background that fulfill 
either Li-Fraumeni syndrome or Li-Fraumeni-like syndrome criteria (Gonzalez et al., 2009; Ruijs et 
al., 2010). Under broader criteria of the Li-Fraumeni phenotype, it has been reported that 14% of 
patients with pathogenic mutations in TP53, which exhibit minor allele frequency of germline 
mutation, carry de novo mutation, i.e. not found in the parents. The de novo pathogenic mutation 
appears to be a consequence of somatic mutation occurring in a gamete cell of one parent or in the 
fertilized egg during early stage of embryogenesis (Batalini et al., 2019). Moreover, not all germline 
TP53 mutation carriers belong to the Li-Fraumeni/Li-Fraumeni-like families. Two population-based 
breast cancer studies reported germline mutation in TP53 among women with early (<40-year) 
onset breast cancer (Lalloo et al., 2006, Mouchawar et al., 2010). Of the unselected breast cancer 
patients in Lalloo (2006) and Mouchawar (2010) studies, 2 out of 63 (3%) and 2 out of 52 (4%), 
respectively, had no family cancer that met the Li-Fraumeni criteria, suggesting that the 
significance of TP53 germline mutation in early-onset breast cancer is larger than previously 
thought and it might be extended outside clinically defined Li-Fraumeni syndrome (Lalloo et al., 
2006; Mouchawar et al., 2010).  
Apart from breast cancer predisposition, germline TP53 mutation may impact the prognosis of 
breast cancer and the treatment outcome. For instance, the R72P (arginine 72 proline) 
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polymorphism has been suggested to affect the survival of breast cancer patients (Tommiska et al., 
2005; Schmidt et al., 2009). It appears that TP53Arg72 induces apoptosis more efficiently than 
TP53Pro72 (Bergamaschi et al., 2006). However, the precise effect of this variation on patients’ 
survival and its magnitude remains uncertain; perhaps partially due to TP53’s diverse and complex 
molecular activity as well as the use of different clinical endpoints to evaluate prognostic 
significance. In addition to patients’ survival, the R72P polymorphism appears to associate with the 
pathologic outcome of chemotherapy as well (Xu et al., 2005; Toyama et al., 2007; Vazquez et al., 
2008). This particular polymorphism was also reported to influence therapy in other cancer types, 
such as its association with the clinical response to cisplatin-based chemoradiotherapy for advanced 
head and neck cancer patients (Bergamaschi et al., 2003). Apart from SNP309 and R72P, only a 
few studies have investigated the association between germline variation in genes involved in the 
TP53 stress response network and patient survival and drug response. A candidate gene study was 
performed by Vazquez et al. on 187 genotyped SNPs that reside in 138 genes involved in mediating 
the TP53 stress response. The study found seven SNPs in five genes with significant genotype-drug 
response association in vitro by using data generated through the NCI anticancer drug screen 
(NCI60 screen). The strongest association was found for SNPs rs6734469 and rs187115 in YWHAQ 
and CD44, respectively (Vazquez et al., 2011). An interaction analysis between haplotype-based 
germline SNPs and TP53 tumor status identified one locus, represented by rs10916264, which 
associated with worse survival among patients with ER-positive and TP53-positive tumors, and 
another locus, represented by rs798755, which was speculated to associate with patient survival in 
interaction with anthracycline treatment (Fagerholm et al., 2017).  
Unlike the association of TP53 germline variation with prognosis and treatment outcomes, the 
effect of TP53 tumor status has been studied extensively (Aas et al., 1996; Bertheau et al., 2002, 
2008) suggesting that TP53 mutant patients have poor overall survival compared to those with the 
wild-type TP53 tumors. The effect is also pronounced among patients with ER positivity, and 
HER2-enriched patients (Silwal-Pandit et al., 2014). While the functional p53 and its apoptotic 
activity are suggested to be essential for the initiation of response to genotoxic stress, such as 
cytotoxic chemotherapy, the predictive value of TP53 status in breast cancer treatment response is 
rather inconclusive. 
The TP53 gene is a trans-regulatory element which resides at 17p13.1 and encodes for the TP53 
tumor suppressor protein. TP53 protein regulates the growth inhibitory genes and its tumor 
suppressor role seems to be linked to its transcription factor function. The diverse gene transcripts 
regulated by TP53, also known as P53-dependent transcriptome, are mostly involved in pathways of 
cell survival and genome stability (Hafner et al., 2019). In the regulatory context, the TP53 level in 
normal condition is within a narrow range of intracellular concentration due to a highly regulated 
process involving the physical interaction of TP53 and the E3 ubiquitin ligase MDM2. The 
ubiquitination of TP53 by MDM2 leads to its continuous degradation which keeps it at low level. 
The phosphorylation of TP53 in response to DNA damage renders it insensitive to MDM2, 
resulting in its accumulation in the cell (Kubbutat, Jones & Vousden, 1997). On the other hand, 
TP53 itself transcriptionally activates MDM2 to form a regulatory feedback loop (Lahav et al., 
2004). MDM2 level is elevated in several cancer cells, including those of the breast (Shaikh et al., 
2016). A common single nucleotide polymorphism (SNP309) in the first intron of MDM2 within 
the promoter region impacts the binding site of a transcriptional activator, resulting in the enhanced 
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level of MDM2 transcript. SNP309 has been suggested to associate with increased incidence of 
early-onset breast cancer (Wasielewski et al., 2007), however in a large study by BCAC, no such 
association was found (Schmidt et al., 2007). Although the MDM2 SNP309 was suggested to 
predict poor survival in other cancers such as leukemia (Gryshchenko et al., 2008), it did not seem 
to predict breast cancer patients’ survival (Toyama et al., 2007; Boersma et al., 2006). However, 
evidence of predisposition to worse breast cancer survival was observed for MDM2 SNP309 in 
combination with TP53 R72P (Schmidt et al., 2009). The first study performed for this thesis 
investigated the breast cancer survival association of candidate TP53 stress response network genes, 
as well as their interaction with TP53 R72P and MDM2 SNP309. 
In the functional context, the TP53-dependent pathways include:  
(1) cell cycle arrest: the TP53-dependent inactivation of pro-cell cycle cyclin-dependent kinases 
through CDKN1A (Engeland, 2018); 
(2) apoptosis: the activation of a set of genes including BAX, PUMA, FDXR and CCNG1 that 
collectively destabilize mitochondria and decrease the threshold of programmed cell death;  
(3) DNA repair: the DNA damage-triggered regulation of a set of genes involved in DNA repair 
pathways such as XPC, GADD45 and DDB2, which together with genes participating in cell 
cycle arrest maintain the genome integrity of the cell (Fischer, 2017);  
(4) metabolic checkpoint: in response to the enhancement of aerobic glycolysis to provide ATP 
and lactate (Warburg effect), TP53 negatively regulates the oncogenic metabolic adaption of 
cancer cells through the regulation of a set of genes, most notably SCO2 (Zhang, Qin & 
Wang, 2010), or by initiating the AMPK-dependent cell cycle arrest/senescence in response 
to glucose deprivation (Jones et al., 2005); 
(5) redox regulation: oxidative stress stimulates the DNA binding activity of certain 
transcription factors including NF-κB, AP-1, and NQO1; the latter of which induce cell 
cycle arrest and apoptosis to maintain the stability of the cell under hypoxia (Paranjpe & 
Srivenugopal, 2013). 
Previous in vitro and in silico evidence (Vazquez et al., 2008, 2010, 2011) suggested the impact of 
TP53 network genes in cancer therapy. That — in addition to a study by Fagerholm et. al (2008) 
which suggested prognostic and predictive potentials for p53 status, along with NQO1, especially 
after anthracycline-based chemotherapy — prompted Study I of this thesis. 
 
2.6 NF-κB 
NF-κB (nuclear factor kappa B) is another transcription factor heavily involved in important 
biological processes including immune and inflammatory responses, survival, senescence, energy 
metabolism, and oxidative stress response. Similar to a number of diverse transcriptional factors, 
such as TP53 and STAT, NF-κB belongs to a class of proteins known as immunoglobulin-fold, 
which are not similar in their sequences but are structurally related (Rudolph & Gergen, 2001). The 
NF-κB transcription factor family consists of five members, namely RelA/p65, c-Rel, RelB, NF-
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κB1 (p50), and NF-κB2 (p52) which generally function as homo- or heterodimers. In absence of 
pathway stimuli, the NF-κB members are bound to IκB (inhibitor of NF-κB), which keeps them 
transcriptionally inactive. Also, similar to TP53 and MDM2, there is a feedback regulatory loop 
between NF-κB and IκB. Upon activation the IκB is phosphorylated, leading to its detachment from 
NF-κB members and its proteasomal degradation. Then, the NF-κB dimers translocate to the 
nucleus to induce or suppress the expression of their target genes (Sethi, Sung & Aggarwal, 2008).  
There are two main pathways (canonical and non-canonical) which lead to the activation of NF-κB. 
The main activating approach, i.e. detaching IκB from NF-κB dimer, as well as some intermediate 
signal transduction factors such as TRAF2, are common in both pathways. The two pathways differ 
mainly in the factors and molecular receptors — such as TNFR1/3 in canonical pathways versus 
BAFFR/TRAIL-R4 in non-canonical pathways — which trigger NF-κB activation. They also differ 
in the intermediate factors, including the IĸB-targeting kinase complexes (IKK) as well as the 
downstream NF-κB members. The IKK complex in canonical pathways consists of IKKα and IKKβ 
kinases and the regulatory subunit IKKγ/ΝΕΜΟ, whereas in non-canonical pathways the NF-κB-
inducing kinase (NIK) does not involve NEMO (Fusella et al., 2017; Hoesel & Schmid, 2013). 
Figure 4 briefly illustrates the two main pathways involved in NF-κB activation. 
 
 
Figure 4. Canonical and non-canonical pathways involved in the activation of diverse NF-κB family 
members. In the canonical pathway, left pane, the pathway-specific signaling factors (e.g. TNFα) activate 
their specific receptors (e.g. TNFR) which lead into the kinase activity of the IKK complex and detachment 
of IĸB from NF-κB dimer. The released NF-κB dimer then translocates into the nucleus for its subsequent 
transcriptional factor activities (Sethi, Sung & Aggarwal, 2008). In the non-canonical pathway, right pane, 
following the activation of receptors (e.g. BAFFR), NIK activates IKKα which lead into phosphorylation and 
proteasomal processing of P100 into P52-P52 which then, along with RelB, is translocated to the nucleus to 
function as a transcription factor. 
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Given the importance of biological processes influenced by NF-κB signaling pathways (such as 
inflammatory response, cell survival, energy metabolism, and oxidative stress response), its 
possible impact on cancer development and treatment efficacy is expected (Karin, 2006). Aberrant 
regulation of NF-κB pathways contribute to the tumorigenesis of breast cancer (Biswas et al., 2004; 
Boehm et al., 2007; Nakshatri et al., 1997). NF-κB level is elevated in breast cancer tumors 
(Cogswell et al., 2000) and appears to vary among subtypes especially depending on ER status. For 
instance, activated NF-κB is detected in ER-negative human breast cancer cells with overexpression 
of ErbB1 (Biswas et al., 2000, 2001, 2003), and the relative level of NF-κB inversely correlates 
with the expression of estrogen receptors, suggesting that they might mutually repress each other 
(Nakshatri et al., 1997; Gionet et al., 2009).  
The association of single nucleotide polymorphism in the NF-κB pathway genes with breast cancer 
prognosis has been little studied so far (Kim, Hagemann & DeMichele, 2009; Murray et al., 2013). 
A breast cancer survival study on SNPs within or in the 100kb flanking region of genes involved in 
human immunology and inflammation suggested that rs4458204, linked to NF-κB-target chemokine 
ligand CCL20, influences breast cancer survival in patients with ER-negative tumors who have been 
treated with chemotherapy (Li et al., 2014). The impact of NF-κB on breast cancer treatment might 
be linked to its mutually repressing relationship with ER, or in a more general aspect, due to its 
elevated activity in cancer cells which induce a survival mechanism by up-regulating anti-apoptotic 
genes (Katsman, Umezawa & Bonavida, 2009), thereby providing a major causative environment 
for drug resistance. The second study performed for this thesis investigated the impact of NF-κB 
signaling pathways on breast cancer patients’ survival and treatment outcome. 
 
2.7 NQO1 
NQO1 (NAD(P)H:quinone dehydrogenase 1) gene resides on 16q22.1 and encodes for NQO1 
which is a multifunctional enzyme involved in cellular defense against cytotoxicity and 
carcinogenicity of quinones, especially under oxidative stress (Talalay & Dinkova-Kostova, 2004; 
Adikesavan, Barrios & Jaiswal, 2007). The cytotoxicity of quinones can arise through the hypoxia 
stress when their one electron is reduced leading to the production of a semi-quinone free radical 
which is attributed to DNA damage. By catalyzing the reduction of quinone to hydroquinone in a 
single two-electron step, NQO1 bypasses the production, and thus the toxicity, of semi-quinone free 
radicals. However, hydroquinone itself can be redox-labile and form cytotoxic reactive oxygen 
species DNA (Ross et al., 2000). 
The reports on the impact of NQO1 on cancer development are controversial, perhaps due to its 
fundamental enzymatic activity which can diversely affect the molecular players of cellular 
environment, as well as its crosstalk with other important signaling pathways such as TP53 and NF-
κB (Thapa et al., 2014). It has been demonstrated that treating NQO1 wild-type cells with 
dicoumarol, an inhibitor of NQO1, abolishes TNF-induced NF-κB activation (Ahn et al., 2006; 
Iskander et al., 2006). NQO1 also regulates TP53 stability and the lack of NQO1 activity promotes 
TP53 degradation which inhibits apoptosis (Asher et al., 2002). It has been suggested that NQO1 
also inhibits the degradation of P33NG1b, a tumor suppressor protein downregulated in several 
38	
	
carcinomas (Garate, Wani & Li, 2010). Dysregulation of NQO1 has been found in several cancer 
types.  
The most notable aberrant form of NQO1 is the null enzyme activity attributed to TT genotype of 
NQO1 C609T (rs1800566) mutation, which was found in eight cancer types, including those of the 
breast (Hamajima et al., 2002). The same mutation was reported to strongly associate with poor 
survival among breast cancer patients, particularly after anthracycline-based adjuvant chemotherapy 
and in TP53-aberrant tumors (Fagerholm et al., 2008). The third study conducted for this thesis 
analyzed immunohistochemical staining of NQO1 and NF-κB, in two series of invasive breast 




MicroRNAs (miRNAs) are short (about 20–22 nucleotides) functional RNAs known as post-
transcriptional regulators of gene expression by either degrading or translationally repressing their 
target mRNAs (Wilczynska & Bushell, 2015). Through the canonical miRNA biogenesis, the 
primary miRNA processor (pri-miRNA) is processed into precursor miRNA (pre-miRNA) followed 
by their transportation from nucleus to cytoplasm. The pre-miRNA are then cleaved by ribonuclease 
Dicer into miRNA duplex, but only one strand becomes mature miRNA and the other strand is 
degraded. Mature miRNAs are loaded into RISC (RNA-induced silencing complex) and bind to the 
complementary sequence of their target mRNAs, which result in translational inhibition and mRNA 
decay (Treiber, Treiber & Meister, 2019). The crosstalk between miRNAs and biologically essential 
signaling pathways, such as TP53 and NF-κB, may play a major role in activation or inhibition of 
pro-tumorigenesis cascade of transcriptional events (Jones & Lal, 2012; Ma et al., 2011).  
There is increasing evidence of the impact of miRNAs on human cancer (Iorio & Croce, 2012). 
Several studies implicated the association of miRNAs and breast cancer pathogenesis and such 
miRNAs can be classified as oncomiRs (Li et al., 2012; Jiang et al., 2010), tumor suppressors 
(Feliciano et al., 2013), metastamiRs (pro-metastatic) (Huang et al., 2008), or metastasis 
suppressors (Tavazoie et al., 2008). Moreover, miRNAs are differentially expressed in breast cancer 
subtypes including basal versus luminal tumors (Blenkiron et al., 2007; Sempere et al., 2007), 
HER2-positive versus HER2-negative tumors, and ER-positive versus ER-negative tumors (Mattie 
et al., 2006; Lowery et al., 2009). Studies also suggest miRNAs as the predictors of breast cancer 
prognosis and treatment sensitivity, for instance: high-circulating (serum) level of miR-202 
significantly correlated with reduced overall survival (Joosse et al., 2014); four-miRNA signature 
(miR-18b, miR-103, miR-107 and miR-652) in breast cancer patient serum associated with relapse-
free and overall survival and can be a prognostic classifier of patients with TNBC (Kleivi Sahlberg 
et al., 2015); high level of miR-125b associates with poor response to Taxol treatment (paclitaxel) 
(Zhou et al., 2010); and high plasma miR-210 associated with poor sensitivity to trastuzumab (Jung 
et al., 2012).  
39	
	
Despite the frequent reports of miRNAs’ contribution to cancer development, to establish the role 
of individual miRNA or group signatures these findings are required to survive the validation tests 
followed by functional studies. 
 
2.8.1 miR-30 family 
The miR-30 family consists of five members (i.e. miR-30a–e) encoded from three different 
genomic locations (miR-30c and miR-30e at 1p34.2; miR-30a at 6q13; and miR-30b and miR-30d 
at 8q24.22), with extremely high sequence homology and 100% conservation in the seed region 
(Kozomara & Griffiths-Jones, 2014). Several studies implicate the role of miR-30 family members 
in biological and pathological processes such as senescence (Martinez et al., 2011), apoptosis (Liu 
et al., 2016; Xia et al., 2010), and autophagy (Zhu et al., 2009). Also, multiple studies have reported 
the downregulation of miR-30 family members in multiple cancer types and metastatic disease, 
including breast (Zhang et al., 2014), lung (Kumarswamy et al., 2012), thyroid (Boufraqech et al., 
2015), HCC (Liu, Tu & Liu, 2014), and gastric cancer (Sousa et al., 2016). However, in some 
cancers, miR-30 family members showed oncogenic features (Li et al., 2012; Gaziel-Sovran et al., 
2011; Dobson et al., 2014). The diverse impact of miR-30 family members is not uncommon and is 
reported even in the well-studied miRNA families such as miR-200 (Elson-Schwab, Lorentzen & 
Marshall, 2010). In general, the differential behavior of miRNAs may be due to several reasons 
such as the variety of their targeting mRNAs, their involvement in diverse functional pathways, and 
the different types of tumors.  
Accumulating studies report the impact of several miR-30 family members in breast cancer 
prognosis, metastasis, chemosensitivity, and treatment outcome. MiR-30a inhibits breast cancer 
proliferation and metastasis by directly targeting the metastasis gene metadherin (MTDH) (Zhang et 
al., 2014). Cheng et al. (2012) demonstrated the suppressive impact of miR-30a on another 
metastatic associated protein, vimentin, which resulted in reduced migration and invasiveness of 
breast cancer cells. Another recent study found that miR-30a is downregulated in TP53-inactivate 
TNBC and associates with reduced outcome (di Gennaro et al., 2019). A study by Bokhorn et al. 
(2013) showed that miR-30c inhibits the chemoresistance of breast tumor through its regulator 
effect on cytoskeleton genes TWF1 and IL-11 which are involved in cell motility, drug sensitivity 
and cancer progression. Higher expression of both miR-30a and miR-30c associates with better 
tamoxifen therapy and longer progression-free survival (Rodriguez-Gonzalez et al., 2011). The 
expression of another miR-30 family member, miR-30e*, appeared as a protective prognostic 
marker in the ESR1+/ERBB2− subtype of breast cancer (D'Aiuto et al., 2015). A study by Li et al. 
(2012) which suggested miR-30d as a significant modifier of patients’ survival in ovarian cancer — 
i.e. an inverse association with patients’ survival — prompted the investigation of miR-30d in 
breast cancer survival in Study IV. The fourth study performed for this thesis found association 





3 Aims of the study 
The objective of this thesis was to investigate key cancer-related pathways and regulatory elements 
to identify prognostic and predictive markers associating with breast cancer patient survival and 
treatment outcome.  
 
The studies performed for this thesis investigated: 
 
• The impact of germline mutation in TP53 regulatory network genes on breast cancer 
survival and treatment outcome. 
• The association between SNPs in the NF-κB activating pathway and breast cancer survival. 
• The associations of NQO1 protein expression and NF-κB nuclear localization with breast 
cancer survival and treatment outcome. 





4 Material and method 
4.1 Study subjects 
4.1.1 Germline DNA samples and genotype information 
	
The Breast Cancer Association Consortium (BCAC) is an international multidisciplinary 
consortium formed in April 2005, dedicated to breast cancer research. There are over 100 groups 
currently contributing to BCAC and providing information about their study subjects including 
genotyping, clinical, demographics, and key epidemiological data 
(http://bcac.ccge.medschl.cam.ac.uk/)(Breast Cancer Association Consortium, 2006, Broeks et al., 
2011). Since the study members are from multiple ethnicities and were designed to benefit different 
scientific investigations, the eligible contributing studies in each BCAC collaborative project may 
be different. 
In Study I (Jamshidi et al., 2013), genotypes of the selected SNPs in the TP53 regulatory network 
were obtained from germline DNA samples in four European studies within BCAC. Genotype data 
was available for altogether 4,701 invasive breast cases, namely the Amsterdam Breast Cancer 
Study (ABCS)(n=1,442), the Hannover Breast Cancer Study (HABCS) (n=794), the Helsinki Breast 
Cancer Study (HEBCS)(n=925), and the Polish Breast Cancer Study (PBCS)(n=1,540) (see Table 2 
for detailed description). HEBCS-GWAS patients included in BCAC, and for whom samples were 
previously genotyped for a genome-wide case-control breast cancer risk study (Li et al., 2010, 
2011), were used as the initial study population followed by further evaluation in the rest of the 
contributing studies and in the pooled dataset. The HEBCS (n=925) peripheral blood samples 
originated from the large Finnish breast cancer study population, which consists of two series of 
unselected breast cancer patients (n=1,870) and additional familial cases (n=540) ascertained at the 
Helsinki University Central Hospital. The unselected set consisted of two cohorts which were 
collected in 1997–1998 and 2000 (Kilpivaara et al., 2005; Eerola et al., 2000), and in 2001–2004 
(Fagerholm et al., 2008), and cover 79% and 87% of all consecutive, newly diagnosed cases treated 
at the hospital at the time of collection, respectively. The additional familial cases were collected at 
Helsinki University Central Hospital, Department of Clinical Genetics, and BRCA1 and BRCA2 
mutation cases had been excluded from the familial patient series (Eerola et al., 2000; Vehmanen et 
al., 1997). Of 925 HEBCS invasive breast cancers, 760 samples were from the unselected and 
familial breast cancer set which were genotyped with Illumina 550k SNP array and an additional 
165 ER-negative samples were genotyped with the Quad610.v1 platform (Li et al., 2010, 2011). 
The TP53 R72P (rs1042522) and MDM2 SNP309 (rs2279744) were genotyped using the TaqMan 
assay (Schmidt et al., 2009). The TP53 R72P was genotyped in PBCS as described previously 
(Garcia-Closas et al., 2007). The genotyping for the PRKAG2 and PPP2R2B SNPs was also carried 
out using Applied Biosystems TaqMan SNP genotyping assays. Genotyping for PRKAG2-02 
(rs4726050) in ABCS and PRKAG2-04 (rs7789699) in PBCS failed to produce high quality 
genotypes; for that reason, these particular results were not included in the analysis. A higher 
frequency of homozygous rare alleles and deviation from the Hardy–Weinberg equilibrium for 
PPP2R2B (rs10477313) was seen among ABCS samples, but the results for this SNP were in line 
with the rest of the studies (Jamshidi et al., 2013).  
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In Study II (Jamshidi et al., 2015), primary data from a total of 24 studies (n=30,431 invasive breast 
cancer cases of European ancestry) participating in BCAC were used (Table 2). To enter the 
analyses, each study was required to have a minimum number of 10 events (death). The germline 
genotype information of the SNPs were obtained from data available in an Illumina iSelect 
genotyping array (iCOGS) which was custom-designed for the Collaborative Oncological Gene-















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































4.1.1.1 SNP selection (applicable to Studies I and II) 
In Study I, following evidence suggesting the involvement of TP53 network genes in cancer therapy 
response (Vazquez et al., 2008, 2010, 2011), and suggestive evidence of the prognostic and 
predictive potential of p53 status, along with NQO1 (Fagerholm et al., 2008), an initial survival 
study was performed in the HEBCS (n=925) cases for SNPs in the regions of five genes. These five 
genes — PRKAG2, PPP2R2B, CCNG1, PIAS1 and YWHAQ — were previously identified by 
Vazquez et al. (2008) by analyzing 187 SNPs residing in 138 TP53 pathway genes for their impact 
on cancer therapy response in vitro. To investigate their effect on breast cancer survival and 
treatment outcome, the HEBCS sample set was employed to investigate all of the tagging SNPs, 
available in BCAC/COGS, representing different haplotypes of these genes. Multiple haplotypes in 
PRKAG2 and one haplotype in PPP2R2B emerged as significant predictors of patient survival in 
HEBCS. To validate the result, three additional studies, i.e. ABCS, HABCS, PBCS, were added to 
the study to be investigated individually, and in a pooled data setting. Thus, the analysis in the 
pooled data (validation) included five SNPs representing different haplotypes in PRKAG2 and 
PPP2R2B: PRKAG2-01 (rs1029946), PRKAG2-02 (rs4726050), PRKAG2-03 (rs6464153), 
PRKAG2-04 (rs7789699)) and PPP2R2B (rs10477313) (Jamshidi et al., 2013). 
In Study II, on the basis of published evidence, including the result provided by Fagerholm et al. 
suggesting the connection between the NF-κB signaling pathway and potential prognostic and 
predictive markers of breast cancer survival and treatment outcome (Fagerholm et al. 2008), 917 
SNPs, which were previously genotyped for BCAC/COGS projects, were selected locating within 
or in a 50kb flanking region of 75 genes suggested to be the components of the NF-κB pathway 
activation by KEGG hsa04064 dataset (www.genome.jp/kegg/) (Kanehisa et al., 2014). The 
selected genes included NF-κB related ligands and receptors (e.g. TNF, TLR1-4, and TNFRSF10A 
and B), membrane molecules (e.g. IRAK2), kinases (e.g. IKBKB), I-kappa-B cascade (e.g. IKBKG, 
IRAK1 and TLR8), cytoplasmic sequestering/releasing of NF-κB (e.g. NF-κBIs and TNFSFs), and 
transcription factors (e.g. NF-κB1 and RELs); but not the T-cell specific elements nor the 
downstream targets of NF-κB (Supplementary Table 8 in Study II) (Jamshidi et al., 2015).  
 
4.1.2 Tumor array samples  
In Studies III and IV, invasive breast carcinoma tumor samples available for TMA (tissue 
microarray) were used. The NQO1 protein expression and NF-κB nuclear localization (inferred as 
activation) were studied in two series of invasive breast tumors.  
The first series, which was also studied in Study IV for in situ detection of miR-30d expression, 
included 884 tumors from unselected breast cancer patients and an additional 542 familial cases. 
The unselected cases were ascertained at the Department of Oncology, Helsinki University 
Hospital, during the years 1997–1998 and 2000 (Syrjakoski et al., 2000; Kilpivaara et al., 2005). 
The additional 542 familial breast cancer cases were collected by systematic screening for family 
history at the Department of Oncology, Helsinki University Central Hospital, or were ascertained 
through genetic counseling at the Department of Clinical Genetics. A total of 1,238 invasive breast 
carcinomas were available for TMA: 423 from cases without familial background of breast cancer 
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and 815 from patients with family history. The familial cases were also identifiable as large families 
with three or more first– or second-degree relatives with breast or ovarian cancer in the family 
(including the proband), and small families with two affected first-degree relatives (including the 
proband). Patients with BRCA1 and BRCA2 mutations were identified and excluded from the 
familial patient series (Vehmanen et al., 1997; Vahteristo et al., 2001, 2002). The tumor samples 
were collected at surgery prior to adjuvant treatment.  
The second series used in Study III included 283 primary tumors of patients with advanced breast 
cancer who participated in a randomized multicenter trial which compared two drugs, Taxotere 
(docetaxel) and methotrexate-fluorouracil (MF), after anthracycline failure in metastatic patients 
(Sjostrom et al., 1999). Of these, 113 primary breast tumors on TMA (Tynninen et al., 2002) were 
available for our analysis. Of the 113 studied tumors, all were scored for NQO1, while 80 were 
scored for NF-κB (Jamshidi et al., 2012). 
 
4.1.3 Fresh frozen tumor samples  
In Studies I and III, the gene expression microarray analysis was performed on fresh frozen breast 
cancer tumors. The total RNA from 187 primary breast cancer tumors, including 155 from 
unselected series and 32 from the additional familial sets, were extracted by the mirVANA miRNA 
Isolation Kit (Life Technologies, Carlsbad, CA, USA). The samples were further processed, and 
hybridized into Illumina HumanHT-12 v3 Expression BeadChips containing 24,660 Entrez Gene 
entities, according to the manufacturer recommendations (http://www.illumina.com). Following the 
MIAME (Minimum information about a microarray experiment) guideline (Brazma et al., 2001), 
the collected data was submitted to the GEO (Gene Expression Omnibus) database (GSE24450) 
(Jamshidi et al., 2012, 2013). 
 
4.2 Clinical and pathological information and tumor characteristics 
4.2.1 Studies I and II 
Each study participating in BCAC submitted the clinical and pathological data of their subjects 
including age of diagnosis, tumor grade, size, nodal status, metastases at diagnosis, histological 
type, estrogen receptor, progesterone receptor, HER2 status, and follow-up and vital status (Broeks 
et al., 2011). Table 2 lists additional publications by each contributing study in BCAC with detailed 
description of the data. 
 
4.2.2 Studies III and IV 
Clinical and pathological information on tumor characteristics, size, nodal status, distant metastasis, 
and estrogen and progesterone receptor status was collected from the pathology reports. A breast 
cancer pathologist re-reviewed all tumors for histological diagnosis and grade according to the 
Scarff-Bloom-Richardson recommendation, modified by Elston and Ellis (Elston, Ellis, 1991). For 
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HER2 status collected from the TMA data, the CISH results were prioritized, i.e. CISH result (0–
1=neg, 2–3=pos); if CISH results were unavailable IHC was used (less than 10% scored 0–1=neg, 
and more than 90% scored 3=pos; score 2 was not used) (Jamshidi et al., 2013). For evaluating the 
p53 expression, breast cancer TMA sections were stained by immunohistochemical methods using 
mouse monoclonal anti-human p53-antibody (DO-7, DAKO) and 20% cutoff was set to determine 
positive and negative status (Tommiska et al., 2005). The Ki-67 expression was determined using 
Ki-67 antibody (Ahlin et al., 2007) with 20% cutoff set to classify positive and negative status 
(Jamshidi et al., 2012). 
The information on death due to breast cancer or other reason was obtained from the Finnish Cancer 
Registry. Information on adjuvant treatment and distant metastases during the follow-up was 
collected from patient records. In Study III, two series of patients were included in the survival 
analyses: first, the extensive series of sporadic and familial non-BRCA1/2 breast tumors, and 
second, those in clinical trials comparing chemotherapy regimens after anthracycline treatment 
failure in metastatic breast cancer.  
 
4.3 Immunohistochemical methods  
4.3.1 Protein expression  
In Study III, TMA was used to assess NQO1 protein expression and NF-κB nuclear localization. 
TMA was constructed using a set of four cores (diameter 0.6 mm) per source block, which was the 
most representative region of each formalin-fixed and paraffin-embedded breast cancer specimen 
(Tommiska et al., 2005). The mouse monoclonal anti-human NQO1-antibody (Santa Cruz, diluted 
1:500) and the rabbit monoclonal anti-human NF-κB (ABCAM, diluted 1:1000) was used to detect 
NQO1 and NF-κB, respectively. The secondary reagents were from Vector Laboratories 
(Burlingame, USA), and the chromogenic substrate enhancement step was performed as described, 
without nuclear counterstaining (Bartkova et al., 2007). For the carriers of homozygous c.558C>T 
variant, only 0–1% of normal breast tissue or tumor cells were immunohistochemically positive for 
NQO1, therefore, the cutoff is generally set at 2% to determine the negative and positive status.  
Consistent with previous studies (Lessard et al., 2005), and our observation of only rare nuclear 
positivity in normal or benign breast tissue (n = 30), the 5% cutoff was set for NF-κB status 
classification, i.e. NF-κB was considered positive/activated when 5% or more cancer cells showed 
nuclear staining and negative when fewer than 5% cells showed nuclear signal. Also, NF-κB was 
considered negative when only cytoplasmic staining was observed (Jamshidi et al., 2012). 
 
4.3.2 miRNA in situ hybridization 
	
In Study IV, miRNA in situ hybridization for detecting miRNA expression was done on formalin-
fixed paraffin-embedded tissue microarray sections as described previously (Li et al., 2012). The 
deparaffinization of slides was carried out in a xylene series and the rehydration step was done 
using an ethanol series (100% to 25%). A ten-minute proteinase K digestion (10ug/ml; Roche) was 
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followed by slides one hour pre-hybridization in hybridization solution consisting of 50% 
formamide, 5XSSC, 500 ug/ml yeast tRNA, and 1X Denhardt’s solution, as well as overnight 
hybridization with double digoxigenin labeled miR-30d locked nucleic acid probe (5’-
CTTCCAGTCGGGGATGTTTACA-3’, 2.5µM; Exiqon) in hybridization solution. The washing 
step (50% formamide, 2XSSC) was performed at hybridization temperature. The anti-digoxigenin-
AP antibody (1:1500 dilution; Roche) and BCIP/NBT substrate (Sigma) were used for the 
chromogenic identification of signals. The evaluation of the results was performed without 
knowledge of the clinicopathological information. The staining was classified as no staining, weak, 
moderate and strong cytoplasmic signals. 
 
4.4 Drug response assay 
In Study IV, the association between miR-30 family members and doxorubicin and lapatinib 
response in vitro was examined through a miRNA mimic/inhibitor-based drug response in breast 
cancer cell lines as described previously (Yadav et al., 2014). The assay ready cell lines used were 
MCF-7 (ER+, PR+, HER2-, p53 wild-type), MDA-MB-361 (ER+, PR+, HER2+, p53 mutated), 
HCC1937 (ER-, PR-, HER2-, p53 mutated), and HCC1954 (ER-, PR-, HER2+, p53 mutated). In the 
validation round, the CAL-120 (ER-, PR-, HER2-, p53 mutated) and MDA-MB-436 (ER-, PR-, 
HER2-, p53 mutated) cell lines were added to the screening. A custom human miRNA library was 
obtained from Ambion (mirVana™ miRNA mimic/inhibitor) on 384-well plates and was used with 
6 replicates in primary and 11 replicates in the replication/validation round. Table 3 lists the specific 
miRNA mimics and miRNA inhibitors for each miR-30 family member. MiRNA inhibitors are 
single-stranded oligonucleotides that bind and inactivate their target miRNA, irreversibly. MiRNA 
mimics are double-stranded oligonucleotides which mimic the corresponding miRNA. The generic 
intra-plate controls used in the screens were acquired from QIAGEN and Ambion (pre-miR 
negative control #2 with 32 replicates, and AllStars Cell Death Control with 12 replicates). The 
concentrations of doxorubicin were 1, 10, 100, 500, 1,000, and 10,000 nM, and for lapatinib were 
0.83, 10, 100, 1,000, 5,000, and 10,000 nM. Cell proliferation was measured 96h after transfection 
by adding 25 ul per well of CellTiter-Glo (Promega) followed by 5 minutes shaking at 600 rpm 
(Titramax 1000, Heidolph) and 5 minutes centrifugation at 1000 rpm (SL40R, Thermo Scientific) 
and luminescence was detected using PHERAstar FS plate reader (BMG Labtech). The secondary 
screening was done similarly as the primary screen. Fluorescence, indicating the number of dead 
cells in each well, was measured using the PHERAstar FS plate reader and subsequently, viable 
cells were detected with CellTiter-Glo 2.0 reagent (Promega) using the Paradigm reader (Beckman 











4.5 Statistical methods and bioinformatics  
4.5.1 Association with tumor characteristics  
In Studies I, III and IV, the statistical analyses for association between the candidate markers and 
tumor characteristics were conducted using IBM SPSS Statistics (SPSS Inc, Chicago, IL, USA). 
Unless otherwise indicated, p-values for evaluation of proportional differences in variants by tumor 
characteristics were calculated using Pearson’s chi-squared tests. Fisher’s exact test was used when 
the number in any category was less than five, and linear-by-linear association chi-squared was 
used for ordinal and binary variables. The significance limit was set at 0.05 (two-sided test). P-
values are two-sided. 
  
4.5.2  Survival and treatment analyses  
The survival analyses were conducted in IBM SPSS Statistics (SPSS Inc, Chicago, IL, USA) for 
Studies I, III and IV, and in R environment for statistical biocomputing (www.r-project.org) for 
Study II. Log-rank tests were used to evaluate the statistical significance of differences between 
Kaplan–Meier curves. Univariate (non-adjusted) and multivariate (adjusted) Cox regression 
analyses were used to estimate survival hazard ratios overall and in various subgroups. To test 
whether the variable is an independent predictor of survival, the multivariate model was adjusted 
for conventional prognostic markers including grade, tumor size (T), nodal status (N), metastasis at 
diagnosis (M) (except when the end point was metastasis), ER, PR, HER2, Ki67 status, and p53 
status when appropriate. When studies were pooled, all Cox models were also adjusted for study. In 
the analyses with adjuvant treatment stratifications, sensitivity analyses were conducted by 
excluding patients who had distant metastasis at the time of diagnosis (M=1) as they had been 
extensively treated for metastatic disease, and reported if any changes were observed. All p-values 
are from two-sided tests. The drug response package in R, drm, was used to fit logistic curves to the 
%inhibition curves. 
miRNA Product	type Ambion	ID Mature	miRNA	Sequence
hsa-miR-30a-5p mirVana	miRNA	mimc MC11062 UGUAAACAUCCUCGACUGGAAG
hsa-miR-30a-5p mirVana	miRNA	inhibitor MH11062 UGUAAACAUCCUCGACUGGAAG
hsa-miR-30b-5p mirVana	miRNA	mimc MC10986 UGUAAACAUCCUACACUCAGCU
hsa-miR-30b-5p mirVana	miRNA	inhibitor MH10986 UGUAAACAUCCUACACUCAGCU
hsa-miR-30c-5p mirVana	miRNA	mimc MC11060 UGUAAACAUCCUACACUCUCAGC
hsa-miR-30c-5p mirVana	miRNA	inhibitor MH11060 UGUAAACAUCCUACACUCUCAGC
hsa-miR-30d-5p mirVana	miRNA	mimc MC10756 UGUAAACAUCCCCGACUGGAAG
hsa-miR-30d-5p mirVana	miRNA	inhibitor MH10756 UGUAAACAUCCCCGACUGGAAG
hsa-miR-30e-5p mirVana	miRNA	mimc MC10037 UGUAAACAUCCUUGACUGGAAG
hsa-miR-30e-5p mirVana	miRNA	inhibitor MH10037 UGUAAACAUCCUUGACUGGAAG
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In Study I, in favor of running models including all patients, a category of missing value was 
included for each separate variable; however, sensitivity analyses were performed which only 
allowed the inclusion of patients with available information for all variables and the result was 
reported if any changes were observed. To evaluate the interaction effects between SNPs and tumor 
feature or treatment, a multivariate Cox regression model was built including the interaction terms 
as well as the main effects (2df each). The follow up time was measured between the date of 
diagnosis to the date of death due to breast cancer (for breast cancer survival) or any reason (for 
overall survival), and right-censored at 10 years. A total of 96% of patients were incident breast 
cancers (criterion: 6 months from the date of diagnosis) (Jamshidi et al., 2013). 
In Study II, the powerSurvEpi package in R was used for power analyses of the survival study. The 
GWAS-SNPs with a minor allele frequency (MAF) <1%, i.e. rarely presented in the population, 
were excluded. Two-way SNP interaction analysis was conducted for recessive (AA = 0, Aa = 0, aa 
= 1) and dominant (AA = 0, Aa = 1, aa = 1) models of inheritance. To evaluate the SNP-SNP 
interaction effect on patients’ survival, the likelihood ratio test was used to compare multivariate 
Cox regression models of pairs of SNPs with and without an interaction term (SNP1+SNP2 vs. 
SNP1+SNP2+(SNP1*SNP2)) (Jamshidi et al., 2015). Based on the likelihood ratio test, p-values of 
the appropriate models for each SNP pair were selected. The multiple testing error was corrected 
using the Benjamini-Hochberg post hoc method. The method is also robust against moderate 
dependency between SNPs, for instance the linkage disequilibrium (Benjamini & Hochberg, 1995; 
Sarkar, 2002). The significant association criteria for the interaction pairs included two stepwise 
thresholds. First, the interactive pairs with p-value <0.01 after correction were selected. Second, a 
threshold for the HR based on the power analysis for each model was considered. The 10-year 
overall survival was defined from the time of diagnosis to the date of death due to breast cancer or 
other reasons (median follow-up time 5.6 years), or to the date of the last follow-up. To allow for 
the inclusion of prevalent cases, time at risk was left censored using date of study entry (Jamshidi et 
al., 2015). 
In Study III, for the first set of patients the survival was measured as time between diagnosis to the 
date of death due to breast cancer or other reasons within 10 years of follow-up, and as 5 years 
survival from metastasis to death, which means the time from distant metastasis to the date of death. 
A total of 996 invasive breast tumors were included in the NQO1-related survival analysis with 208 
events. A total of 1,030 invasive breast tumors with 220 events were included in the NF-κB-related 
survival analysis. The median follow-up time for 10-year survival analysis was 112 months. From 
the second series of patients (n=283), a total of 113 tumors were available for TMA, of which 113 
were included in the NQO1-related analysis and 80 in the NF-κB-related analysis. The response 
was determined based on the WHO recommendations (Miller et al., 1981). Parameters such as 
treatment response, time to progression (TTP), and overall survival (OS) from start of anthracycline 
treatment preceding randomization were analyzed. In survival analysis, the clinical response was 
categorized to response (complete or partial) and non-response (no change and progression). 
Anthracycline-treated Overall survival (AOS) was calculated as the time between the beginning of 
anthracycline treatment until death. Anthracycline-treated Time to progression (ATTP) was 
calculated from the start of anthracycline treatment till disease progression. AOS and ATTP were 
collectable for 70 and 55 tumors in NQO1 and NF-κB analyses, respectively. Time to progression 
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(TTP) on methotrexate-5-FU or docetaxel was calculated as time between the date of randomization 
and disease progression (Jamshidi et al., 2012).  
In Study IV, the survival time was calculated for 10 years breast cancer survival (BCS), i.e. the time 
from diagnosis to the date of death due to breast cancer, and 5 years breast cancer death or distant 
metastasis (BDDM), i.e. time between diagnosis and distant metastasis or breast cancer death, or the 
end of follow-up time within five years. All patients included in this study were incident cases: 
entering the study before or in less than 6 months from the date of diagnosis. 
 
4.5.3 Expression quantitative trait loci (eQTL) analysis 
In Study II, data from The Cancer Genome Atlas (TCGA) and METABRIC project (Curtis et al., 
2012; Dvinge et al., 2013) was applied to evaluate the correlation between the candidate loci and 
gene expression by cis-eQTL analysis which was conducted with R package Matrix eQTL 
(Shabalin, 2012) using linear regression and ANOVA models. Peripheral blood DNA SNP 
genotyping data, as well as expression data, were obtained for 913 primary breast tumors available 
in TCGA dataset. Additionally, expression data of healthy breast tissues was retrieved for 85 out of 
the 913 TCGA cases. The TCGA expression data is from level 4 RNA-Seq (upper quartile 
normalized RSEM expression estimates). TCGA-matched peripheral blood DNA SNP genotype 
data is from level 2 Birdseed files (genotyped on Affymetrix Genome-Wide Human SNP Array 6.0 
and processed using Birdseed). The METABRIC data (genotyped on Affymetrix SNP 6.0 platform) 
was retrieved from the European Genome-phenome Archive (cancergenome.nih.gov). The raw 
genotype data was processed by the Affymetrix Genotyping Console Software, according to the 
instruction of Affymetrix Best Practices SNP 6.0 Analysis Workflow. The quality control was done 
by Contrast QC, with the sample quality threshold of <0.4 and genotype calling by Birdseed v2 
with call rate threshold set at >95%. The process resulted in altogether 1,328 samples with both 
genotype and expression data from breast tumor tissues (Jamshidi et al., 2015).	
 
4.5.4 Gene expression microarray analysis 
In Studies I and III, the raw data was imported into R (http://cran.r-project.org) and analyzed by 
methods included in Bioconductor facilities (Gentleman et al., 2004), and quality checked 
according to the Illumina microarray pipeline (Du, Kibbe & Lin, 2008). The data was normalized 
by the quantile method (Bolstad et al., 2003). The gene expression matrix was formed by averaging 
the probes which were matched to the same Entrez Gene IDs (Tatusova, 2010). The Pearson’s 
correlation was evaluated for each gene expression and the nominal p-values were adjusted with 
Benjamini–Hochberg post hoc correction. The threshold for corrected p-value for further analyses 
and functional annotation was set for less than 0.01 (Benjamini & Hochberg, 1995). In Study IV, 
the gene expression analysis in METABRIC was conducted in R using Spearman’s rank correlation. 
Functional annotation and enrichment analyses were studied using the DAVID microarray 
functional annotation tool and Ingenuity Pathway Analysis (IPA) (QIAGEN Inc., 




4.6 Ethical aspects 
All studies were carried out with patients’ written informed consent and the permission from the 
Helsinki University Hospital Ethical Committee (Dnro207/E9/07 and Dnro272/13/03/03/2012). 
Each study contributing to BCAC shared data according to the ethical framework and followed 
national protocol for patients’ participation and was approved by the appropriate local institutional 
review committee. All studies were performed following the reporting recommendations for tumor 





5.1 Germline variations in TP53 network genes 
Study I investigated the association between the germline variations in five TP53 network genes 
which were previously suggested to impact drug response in vitro (Vazquez et al., 2008, 2010, 
2011), i.e. PRKAG2, PPP2R2B, CCNG1, PIAS1 and YWHAQ, and breast cancer patients’ survival 
and treatment outcome. The studied variations included all the SNPs in regions of these five genes 
which were available from a previously genotyped GWAS case-control study (Li et al., 2010, 
2011). The initial study population was HEBCS (n=925). Five SNPs — namely, PRKAG2-01 
(rs1029946), PRKAG2-02 (rs4726050), PRKAG2-03 (rs6464153), PRKAG2-04 (rs7789699), 
PPP2R2B (rs10477313) — which showed significant survival association in HEBCS 
(Supplementary Table 1 in Study I) were further analyzed in the pooled data including the additional 
BCAC studies, i.e. ABCS (n=1,442), HABCS (n=794), and PBCS (n=1,540) (Tables 1 and 2 in 
Study I). Additionally, we investigated the survival and therapy impact of the interaction of these 
SNPs with TP53 R72P and MDM2 SNP309 which were previously suggested to have a combined 
effect on patients’ survival (Schmidt et al., 2009). With the exception of TP53 R72P, all of the 
SNPs exhibited some variation in genotype frequency among the studies (Supplementary Table 2 in 
Study I), due to different allele frequencies in different populations. 
 
5.1.1 Association with tumor clinical and pathological features 
Tumors homozygous for PRKAG2-01 (rs1029946) rare G allele were more often TP53-negative (p 
= 0.005). Homozygous carriers of PRKAG2-02 (rs4726050) rare G allele less often developed high 
grade tumors (p = 0.005) whereas PRKAG2-04 (rs7789699) rare A allele carriers were frequently of 
high grade tumors (p = 0.001), with a dose-dependent effect of the rare allele associating with 
higher grade (Chi square for trend: p = 0.002). Also, the progesterone receptor negative status was 
more frequent in homozygous carriers of PPP2R2B (rs10477313) rare A allele (p = 0.002) 
(Supplementary Table 3 in Study I). 
 
5.1.2 Association with patients’ survival  
The association between SNPs in PRKAG2 and PPP2R2B was analyzed in pooled data using the 
univariate (non-adjusted) and multivariate (adjusted) Cox regression models. The multivariate 
model was adjusted for conventional prognostic markers, i.e. grade, T, N, M, ER, PR, as well as 
study and age of diagnosis. Supplementary Table 3 in Study I illustrates the hazard estimates of both 
univariate and multivariate analyses for SNPs with significant survival association. Patients 
carrying homozygous PRKAG2-01 (rs1029946) rare G allele had improved 10-year overall survival 
compared to carriers of the common A allele (HRnon-adjusted = 0.53, 95% CI = 0.3–0.9; p = 0.023 for 
GG vs. AA/AG). The effect is visualized with Kaplan–Meier plots (Figure 1a in Study I). The result 
was also consistent among all the studies in the pooled data (Supplementary Table 5 in Study I). 
PRKAG2-01 (rs1029946) remained an independent predictor of survival after adjustment for 
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conventional prognostic markers as well as age of diagnosis and study (HRadjusted = 0.57, 95% CI = 
0.3–0.9; p = 0.044). An additional multivariate Cox regression model was built by adding the p53 
status to the model because of the observed association between PRKAG2-01 (rs1029946) and p53 
tumor status. Although the number of patients with complete information for all variables which 
could be included in this model was highly reduced, the overall survival remained the same but it 
was no longer significant (HRadjusted = 0.54, 95% CI = 0.2–1.0; p = 0.137 for GG vs. AA/AG). 
We observed suggestive evidence of lower risk of death for carriers of PRKAG2-02 (rs4726050) 
rare G allele (AG/GG) compared to AA carriers (HRnon-adjusted = 0.85, 95% CI = 0.7–0.9; p = 0.049 
for AG/GG vs. AA) (Figure 1b in Study I). The hazard estimate was not consistent among the 
studies, i.e. HABCS (HR = 1.18, 95% CI = 0.8–1.7) (Supplementary Table 6 in Study I), and the 
association was not significant in the multivariate model. For the rest of the SNPs, we observed 
nominally significant association with patients’ survival (Supplementary Table 3 in Study I); 
however, the effect seems to be driven only by the discovery HEBCS population with no effect on 
the other studies. The survival association observed in HEBCS for the remainder of SNPs, namely, 
PRKAG2-03 (rs6464153) and PRKAG2-04 (rs7789699), was not found in the pooled data. Also, 
none of the studied SNPs showed significant association with patients’ survival in the respective 
subgroups of p53-positive and ER-positive observed in the discovery analyses. 
To investigate the combined effect of each of the studied SNPs with either TP53 R72P or MDM2 
SNP309, the survival analyses were stratified by these two SNPs. Patients carrying the PRKAG2-02 
(rs4726050) rare G allele had better breast cancer survival confined only to MDM2 SNP309 rare G 
allele carriers (HRnon-adjusted = 0.45, 95% CI = 0.2–0.7, p = 0.001 for PRKAG2-02 GG in MDM2 
SNP309 TG/GG compared to the rest of the carriers). Figure 2 in Study I illustrates the Kaplan–
Meier plots of cumulative survival for patients carrying each PRKAG2 (rs4726050) genotype within 
one group of MDM2 SNP309 genotype. Moreover, in a multivariate Cox regression model, 
including the interaction term as well as the main effects (2df each), the interaction association with 
survival remained significant (HRadjusted = 0.59, 95% CI = 0.3–0.9; p = 0.047). There was no 
indication of significant interaction between the remaining SNPs and either of TP53 R72P or 
MDM2 SNP309. 
Patients carrying PP2R2B (rs10477313) rare A allele (GA/AA) had increased survival compared to 
the carriers of GG genotype (p = 0.018) (Figure 3a and Table 3 in Study I). The effect also 
remained significant when corrected for conventional prognostic factors using the multivariate Cox 
regression model (HRadjusted = 0.83, 95% CI = 0.7–0.9; p = 0.034) (Table 3 in Study I). To evaluate 
the impact of the studied SNPs and treatment outcome, the dataset was stratified by either 
chemotherapy or hormonal treatment. Of the studied SNPs, PPP2R2B (rs10477313) appeared to 
associate with patients’ survival after adjuvant hormonal therapy, i.e. patients carrying rare A allele 
(GA/AA) had improved overall survival compared to GG genotype carriers (HRnon-adjusted = 0.66, 
95% CI = 0.5–0.9; p = 0.048 for GA/AA vs. GG), whereas no differential survival was observed 
among those who had not received hormonal treatment (HRnon-adjusted = 0.87, 95% CI = 0.7–1.1; p = 




5.1.3 Association with gene expression level, and functional annotation  
There was no significant correlation between the SNPs in PRKAG2 and PPP2R2B SNPs and gene 
expression in the HEBCS dataset. However, the gene expression analysis of microarray data of 187 
Finnish cases with primary breast tumors (Supplementary Table 2 in Study I) showed that higher 
PRKAG2 expression associates with decreased breast cancer patient survival (HR = 8.6, 95% CI = 
1.3–56.1, p = 0.024) (Supplementary Figure 1 in Study I). Additionally, the higher expression level 
of PPP2R2B correlated with improved patient survival (HR = 0.03, 95% CI = 0.002–0.565, p = 
0.019) (Supplementary Figure 2 in Study I). The limited number of patients in a hormone-treated 
subset of patients did not allow for the survival analysis by PPP2R2B. 
 
5.2 Germline variations in NF-κB network genes 
In Study II, to evaluate the association between germline variations in the NF-κB activating 
pathway and patients’ survival, a set of markers including 917 SNPs residing within or in the 50kb 
flanking region of 75 candidate genes involved in the activation of the NF-κB pathway was applied. 
The panel of markers used in this study was provided by a custom Illumina iSelect genotyping array 
(iCOGS) designed for the Collaborative Oncological Gene-environment Study (COGS) 
(Michailidou et al., 2013). A total of 24 BCAC studies contributed to this study with altogether 
30,431 invasive breast cancer cases of European ancestry (Table 2). Using a multivariate Cox 
regression model (see section 4.5.2), this study focused on two SNP interactions and their 
association with patients’ survival and treatment outcome under both recessive (AA = 0, Aa = 0, aa 
= 1) and dominant (AA = 0, Aa = 1, aa = 1) models. Given the sample size (n = 30,431, death = 
3,375) and the average MAF of 23.4%, the analysis carried 80% power to identify survival 
association with HR above 1.4 (or 1/1.4 = 0.6) and HR of 6.2 (or 1/6.2 = 0.16) in the dominant and 
recessive models respectively. 
 
5.2.1 Association with patients’ survival 
Under the recessive model, a pairwise interaction between rs5996080 (A/G, MAF = 8%) and 
rs7973914 (G/A, MAF = 40%) was observed to associate with patients’ survival, i.e. carriers of the 
homozygous rare allele for both SNPs (rs5996080-GG, rs7973914-AA) showed poor overall 
survival compared to carriers of at least one common allele (HRinteraction = 6.98, 95% CI = 3.3–14.4, 
p = 1.42E-07) (Table 1 in Study II). Also, the likelihood ratio test comparing multivariate Cox 
regression models assuming no interaction versus the model with the interaction term indicated that 
the interaction term was an improved predictor of survival (plikelihood-ratio-corrected = 0.003) (Table 1 in 
Study II). The comparison of absolute uncorrected survival rates of genotype combination is 
illustrated by Kaplan–Meier plots (Figure 1 in Study II). The same interaction analyses were 
conducted for SNPs in linkage disequilibrium with the interacting pair (Supplementary Table 3 in 
Study I). Due to the limited number of events (<5), no subgroup analyses were conducted for the 
interacting SNP pair. 
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The SNP rs5996080 of the recessive pair is located on chromosome 22 at 31.5kb downstream of 
NF-κB pathway gene BAFFR (B-cell activating factor receptor, also known as TNFRSF13C). There 
is strong linkage disequilibrium (r2 = 1) with 15 SNPs residing in BAFFR. rs7973914 resides in 
chromosome 12, and lies 8kb upstream of the NF-κB pathway gene TNFR3 (TNFR superfamily 
member 3, also known as LTBR) and 27kb upstream of TNFR1 (TNFR superfamily member 1a, 
also known as TNFRSF1A). The haplotype surrounding rs7973914 is short with very few SNPs on 
it. 
Under the dominant model, an interacting SNP pair (rs17243893 (A/G, MAF = 5%) and 
rs57890595 (A/C, MAF = 11%)) was found to associate with patient survival, i.e. patients carrying 
at least one rare allele for both variants (rs17243893-AG+GG, rs57890595-AC+CC) had improved 
overall survival compared to those with common homozygous genotypes (HRinteraction = 0.51, 95% 
CI = 0.3–0.6, p = 2.19E-05) (Table 2 in Study II). When comparing the two multivariate models 
with and without the interaction term, the interaction was statistically significant (plikelihood-ratio-corrected 
= 0.005) (Table 2 in Study II), Figure 2 in Study II illustrates the Kaplan–Meier curves of the 
differential survival among genotype combination categories. Similar interaction analyses 
performed for SNPs in linkage disequilibrium with the interacting pair are listed in Supplementary 
Table 4 in Study II. The survival association of the interacting SNP pair was consistent among the 
subgroups but there was no differential association confined to any specific subgroup. 
The SNP rs17243893 resides on chromosome 9, and lies in the intron of NF-κB pathway gene 
TRAF2 (TNF receptor associated factor 2). The other SNP, rs57890595, is on chromosome 8, 
within the intron of NF-κB pathway gene TRAIL-R4 (TNF-related apoptosis ligand receptor 4, also 
known as TNFRSF10D). Two other NF-κB pathway genes nearby this SNP include TNFRSF10A 
and TNFRSF10C. 
 
5.2.2 Association with tumor clinical and pathological features 
Of the two interacting SNP pairs, the genotype combinations of the pair found under the dominant 
model (rs17243893 and rs57890595: Aa+aa+Bb+bb vs the rest) associated with nodal status (N) (p 
= 0.010), and might associate with metastasis at diagnosis (M), although it is not statistically 
significant (Supplementary Tables 6a and b in Study II). 
 
5.2.3 Association with gene expression level, and functional annotation 
 
Using TCGA and METABRIC datasets, the eQTL analysis was conducted to investigate the 
association between the interacting SNP pairs and the expression level of the corresponding genes 
in the NF-κB activating pathway. All genotyped SNPs in linkage disequilibrium with the interacting 
SNP pairs (r2 > 0.1) were analyzed. The SNP pairs were available in neither TCGA nor 
METABRIC but they were represented through linkage disequilibrium. 
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For the interacting SNP pair under the recessive model, the rs5996080 proxy (rs9620000, r2 = 1) 
correlated with elevated level of BAFFR in both the TCGA tumor (p = 0.049) and METABRIC 
datasets (p = 0.003). Moreover, other rs5996080 proxies also associated with the expression level of 
TNFR1 and TNFR3, which are the corresponding genes to the other SNP in this interacting SNP 
pair. In detail, the rs5996080 proxy (rs17002737, r2 = 0.79) correlated with the expression level of 
TNFR1 (p = 0.049), with multiple other SNPs in the locus positively associating with the expression 
of TNFR3 (rs2269658: r2 = 0.5, D’ = 0.8, p = 0.00006; rs9620000: r2 = 1, p = 0.003; rs5996088: r2 = 
1, p = 0.002; rs1023497: r2 = 0.4, D’ = 1, p = 0.01; and rs133367 r2 = 0.2, D’ = 1, p = 0.04). The 
number of rs7973914 proxies available in both datasets was limited to four, and none of them 
showed significant association with the expression level of TNFR1/3 or BAFFR. 
The few proxies available for rs17243893 in the interacting SNP pair under the dominant model 
(rs17243893 and rs57890595) did not show any significant association with the expression level of 
TRAF2, nor with TRAIL-R4. An rs57890595 proxy in the TCGA tumor data (rs12546238, r2 = 0.2), 
and one (rs4278155, r2 = 0.2) in the normal tissue data (n = 85), associated with the level of TRAIL-
R4 (p = 0.004). Additionally, in the METABRIC dataset, an rs57890595 proxy (rs4871880, r2 = 
0.1) correlated with the expression of TRAF2 (p = 0.0006). 
The ENCODE-based functional annotations at the Haploreg and RegulomeDB databases of human 
mammary epithelial cells (HMEC) were used to study the functional role of the interacting SNP 
pairs or their proxies, and to investigate the possibility of the SNPs locating in the genomic 
regulatory elements. A total of 35 proxies for rs5996080, from the recessive SNP pair, were likely 
to modify the transcription factor binding motifs, histone modifications, DNase sites and protein 
binding regions in HMEC. Out of the 35 SNPs, 26 were in strong LD with rs5996080 (r2 and/or D’ 
> 0.8). The regulatory annotation identified 22 SNPs in regions with enhancer histone marks, 10 
SNPs in promoter histone marks, and 6 SNPs in Dnase hypersensitivity sites (Supplementary Table 
7a in Study II). In addition to SREBF2 (the host gene for rs5996080), ENCODE annotated genes 
corresponding to the above-mentioned regulatory modifications included BAFF, MEI1, and 
SHISA8. An rs5996080 proxy (rs117492772, r2 = 0.86) was annotated to modify the putative 
transcription factor binding motif of NF-κB. Also, rs5996080 is predicted to alter the putative motif 
binding of Erα-a. For the other SNP in the interacting pair, rs7973914, four proxies were identified 
to reside in the regulatory regions with enhancer histone marks in HMEC (Supplementary Table 7b 
in Study II). The SNP pair in the dominant model, 17243893 and rs57890595, were located in short 
haplotype/undefined haplotypes and therefore, the in silico analyses were limited. Two rs17243893 
proxies (rs17243893 and rs35253986, r2 = 1 and 0.27, respectively) were identified which were 
mapped to regions with enhancer histone mark and Dnase hypersensitivity sites in HMEC dataset 
(Supplementary Table 7c in Study II). 
 
5.3 NQO1 protein expression and NF-κB activation 
To investigate the clinical implication of NQO1 and NF-κB expression, an immunohistochemical 
study was conducted in two series of breast cancer patients’ tumors, i.e. the primary tumors of a 
series of unselected patients and additional familial cases, and the primary tumors of a series of 
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patients who had been treated for metastatic disease. Of the 1,238 tumors available for TMA in the 
first series of patients, NQO1 and NF-κB staining results were retrieved for 996 (80%) and 1,030 
(83%) tumors, respectively (Figure 1 in Study III). NQO1-positive expression was observed in 823 
(83%) and NF-κB nuclear localization (inferred activation) was found in 117 (11%) of the tumors. 
Since there was no difference in NQO1 expression and NF-κB activation by familial history (Tables 
1 and 2 in Study III) all tumors were combined for the analyses. In the second set of patients, the 
NQO1 and NF-κB staining results were available for 113 and 80 tumors, respectively. Positive 
expression of NQO1 was found in 64% and NF-κB activation was found in 15% of the analyzable 
tumors, respectively (Supplementary Table I in Study III). 
 
5.3.1 Association with tumor clinical and pathological features 
The expression of NQO1 and the nuclear localization/activation of NF-κB inversely correlated with 
each other (p = 0.012). Moreover, a direct association was found between NQO1-negative 
expression and the ER-negative status of the tumors (p = 0.011). In line with the published impact 
of the NQO1*2 (rs1800566) variation, the expression of NQO1 correlated with NQO1*2 
(rs1800566) homozygous rare T allele (p < 0.0001). Tumors with TT (Ser/Ser) genotype were all 
NQO1 protein negative (n=24, 100%), whereas tumors with homozygous wild-type C allele 
(Pro/Pro) (n=171/264, 64%) as well as heterozygous genotype carriers (n=541/573, 94%) were 
NQO1-positive (Table 1 in Study III). Nuclear localization/activation of NF-κB associated with 
tumors of ductal carcinomas (p = 0.017), ER-positive status (p = 0.001), and those of the lower 
grade (p = 0.014) (Table 2 in Study III). There was no significant association between either NQO1 
expression or NF-κB activation and the clinicopathological feature of tumors in the second series of 
patients (Supplementary Tables 2 and 3 in Study III). 
 
5.3.2 Association with patients’ survival  
NQO1 protein expression did not modify the survival pattern among all patients or in subgroups of 
patients who had received chemotherapy (Figure 2 and Table 3 in Study III). Similarly, in the 
second series of patients who have received chemotherapy for the metastatic disease, there was no 
significant association between NQO1 protein expression and patients’ overall survival, or in 
subgroup analyses stratified for first-line anthracycline treatment or after second-line docetaxel 
treatment (Supplementary Figures 1a–c and Table 4 in Study III). Negative expression of NQO1 
appeared to accelerate the progression of the disease after second-line methotrexate-fluorouracil 
therapy (HR = 1.99, 95% CI = 1.04–3.78, p = 0.03) (Supplementary Figure 1d and Table 4 in Study 
III). No significant association was found between the nuclear localization/activation of NF-κB and 
patients’ survival in either of the datasets (Figure 3 and Supplementary Figure 2 in Study III). In 
both series of patients, the NQO1 and NF-κB expression appeared to have an inverse pattern of 
survival after adjuvant anthracycline treatment (poor survival for patients with negative NQO1 or 
nuclear localization/activation of NF-κB); however, the trend was not statistically significant 




5.3.3 Association with gene expression level, and functional annotation  
 
The microarray analysis of total RNA extracted from 183 primary breast tumors revealed 877 
genes, which significantly correlated with NQO1 expression (293 positively and 584 negatively 
correlated) and 2,871 genes significantly correlated to NF-κB1 expression (1,635 positively and 
1,236 negatively) with adjusted p-value < 0.01 (Supplementary Tables 4 and 5 in Study III). Of the 
genes negatively correlating with NQO1 are TNF, along with 12 other genes linked to the TNF/NF-
κB pathway, and four genes connected to the toll-like receptor (TLR) family. Of the total of 193 
genes correlated with both NQO1 and NF-κB1, only one gene, LIMA1, positively correlated with 
both of them, whereas 59 genes correlated positively with NQO1 but negatively with NF-κB1, and 
133 genes correlated positively with NF-κB1 but negatively with NQO1 (Supplementary Table 6 in 
Study III). None of the genes showed negative correlation with both NQO1 and NF-κB1. 
The observed opposite pattern was also reflected in the functional annotation of the gene families 
correlated with NQO1 and NF-κB1. The genes with functions known to be related to NQO1, i.e. 
oxidation/reduction, lipid biosynthesis, steroid metabolism, and endoplasmic reticulum positively 
correlated with NQO1 and negatively correlated with NF-κB1. Consistently, gene families 
connected to immune response, lymphocyte activation, JAK-STAT signaling, and apoptosis, which 
are known to associate with NF-κB pathways, were significantly overabundant among the group 
which positively correlated with NF-κB1 and negatively correlated with NQO1 (Figure 4 in Study 
III). 
 
5.4 miR-30 family members 
In a series of sporadic and familial cases, the in situ hybridization (ISH) was performed to assess the 
expression of miR-30d in 1,238 invasive breast carcinomas available for TMA studies. The miR-
30d expression level was studied for its association with patients’ survival, as well as the 
clinicopathological characteristics of the tumor. Furthermore, drug sensitivity screening was 
conducted to evaluate the impact of the entire miR-30 family members on drug response in breast 
cancer cell lines in vitro. Of 1,238 tumor samples, miR-30d in situ hybridization results were 
obtained for 1,193 (96.3%) tumors: 361 (30.3%) tumors had none or low and 832 (69.7%) tumors 
had high intensity of cytoplasmic staining (Figure I in Study IV). The miR-30d expression levels 
were not assessed for the remaining 45 (3.7%) tumors, due to loss of cores during the sectioning or 
staining steps, or cores not containing enough tumor material. However, since no difference was 
observed in gene expression, clinical and pathological association and survival rates neither 
between miR-30d absent and low tumor expression nor between intermediate and high expression, 
the groups were combined for analysis, i.e., “low expression” = absent and low tumor expression 




5.4.1 Association with tumor clinical and pathological features 
Increasing miR-30d expression associated with ductal histopathological type (p = 0.003), higher 
tumor grade (p = 0.0002), positive nodal status (p = 0.007) and higher proliferation rate estimated 
by Ki67 (p = 0.014). Moreover, tumors with higher miR-30d expression were more frequently 
ER/PR+HER2+ whereas those with lower miR-30d expression were more often ER/PR+HER2- (p 
= 0.032) (Table 4). 
 
Table 4. Association of miR-30 expression level with tumor features (unpublished data).
 
miR-30d
Total Low High p.
n(%)
Tumour	histology
Ductal	carcinomas 838 233 605 0,003
70,2% 64,5% 72,7%
Lobular	carcinomas 222 90 132
18,6% 24,9% 15,9%
Medullary	carcinomas 15 3 12
1,3% 0,8% 1,4%
Other 118 35 83
9,9% 9,7% 10,0%
Grade
1 281 96 185 0.0002
23,9% 27,0% 22,5%
2 547 183 364
46,5% 51,5% 44,3%
3 349 76 273
29,7% 21,4% 33,2%
Tumor	size
1 694 213 481 0,417
58,9% 60,2% 58,3%
2 410 115 295
34,8% 32,5% 35,8%
3 40 16 24
3,4% 4,5% 2,9%






Negative 645 214 431 0,007
54,9% 61,0% 52,4%
positive 529 137 392
45,1% 39,0% 47,6%
Metastasis	at	diagnosis
Negative 1 147 347 800 1,000
97,0% 96,9% 97,0%
Positive 36 11 25
3,0% 3,1% 3,0%
ER 	status	
Negative 234 70 164 0,872
20,6% 21,0% 20,5%
Positive 900 263 637
79,4% 79,0% 79,5%
PR	status	
Negative 379 124 255 0,113
33,5% 37,0% 32,0%
Positive 753 211 542
66,5% 63,0% 68,0%
p53		tumor	status
Negative 899 264 635 0,160
80,1% 82,8% 79,0%
Positive 224 55 169
19,9% 17,2% 21,0%
HER2	status
Negative 984 298 686 0,064
87,1% 90,0% 85,9%
Positive 146 33 113
12,9% 10,0% 14,1%
Ki67		tumor	status	(proliferation	marker)
Negative 786 250 536 0,014
67,2% 72,5% 65,0%
Positive 383 95 288
32,8% 27,5% 35,0%
TOP2A	tumor	status	(proliferation	marker)
Negative 573 180 393 0,001
60,6% 69,5% 57,2%
Positive 373 79 294
39,4% 30,5% 42,8%
SubTypes
ER/PR	pos	and	HER2	neg 778 232 546 0,032
72,6% 76,1% 71,2%
ER/PR	pos	and	HER2	pos 91 14 77
8,5% 4,6% 10,0%
ER/PR	neg	and	HER2	pos 52 17 35
4,9% 5,6% 4,6%





5.4.2 Association with patients’ survival  
In order to avoid long-term survivors in ascertainment, the survival analyses were performed only 
among the incident cases. Among the 659 incident cases, 205 (31.1%) had none or low and 454 
(68.9%) had high level of miR-30d expression. The endpoint used in the survival analyses was five 
years breast cancer death or distant metastasis free survival (5-year BDDM). Increased miR-30d 
expression associated with improved patients’ survival (HR = 0.64, 95% CI = 0.44–0.94, p = 
0.024). The expression of miR-30d remained an independent predictive factor of 5-year BDDM in a 
multivariate Cox regression model adjusted for common prognostic factors (HR = 0.44, 95% CI = 
0.29–0.66, p < 10-3). In the subgroup analysis, the increased level of miR-30d associated with 
improved 5-year BDDM among patients with: ER-negative tumors compared to ER-positive (p = 
0.009); HER2-positive tumors compared to HER2-negative (p = 0.004); highly proliferating tumors 
indicated by high expression of Ki67 (p = 0.0002); patients with p53-positive (mutated) tumors 
compared to p53-negative (p = 0.011); and among patients who received anthracycline-based 
chemotherapy compared to those who did not (p = 0.028) (Table 5). The absolute uncorrected 
survival difference is illustrated by Kaplan–Meier curves in Figure 5.  
 
Table 5. For 5-year breast cancer death or distant metastasis of incident cases: A) Univariate Cox regression 
analysis by miR-30d in all patients, and by miR-30d in patients subgrouped by ER, HER2, Ki67, and 
chemotherapy status. B) The multivariate Cox regression analysis by miR-30d was adjusted for conventional 
prognostic factors, i.e. grade, tumor size, nodal status, ER (from medical records; cut-off: >10% as positive, 
<10% as negative), PR (same as ER), Ki67 (cut-off: ≥20% as high, <20% as low), and HER2 (CISH cut-off: 














Figure 5. Kaplan–Meier plots of differential survival by miR-30d expression among all patients and in subgroups 
of ER-negative, ER-positive, HER2-negative, HER2-positive, Ki67-negative, Ki67-positive, no chemotherapy, 




5.4.3 Drug sensitivity screening 
	
The result of survival analysis in the subset of patients who received anthracycline-based 
chemotherapy suggested a possible association between miR-30 and anthracycline-based therapy 
outcomes. No clinical data was available to perform a survival analysis on anti-HER2 outcomes, as 
the treatment was not used at the time when the studied cohorts were ascertained. However, 
following the clinical evidence implicating an association between miR-30 expression and patients’ 
survival by HER2 status of the tumors, an exploratory in vitro analysis was conducted to investigate 
the impact of miR-30 family members in response to anti-HER2 treatment. A dose-dependent drug 
sensitivity screening was conducted testing two drugs: doxorubicin, an anthracycline-based 
chemotherapy, and lapatinib, a dual inhibitor of HER2. The human breast cancer cell lines involved 
in doxorubicin screening included HCC1937, MDA-MB-361, MCF7, and the lapatinib screening 
was performed in HCC1954, which is a HER2-positive breast cancer cell line. In the 
replication/validation round, in addition to the above-mentioned cell lines, MDA-MB-436 and 
CAL120 were added to the screening. Figure 6 illustrates the workflow of the primary and the 
replicatory/validation round of drug screening. 
























































































































































For each miR-30 family member, i.e. miR-30a–e, a specific miRNA mimic and miRNA inhibitor 
was acquired (described in section 4.4) and every drug-treated cell line were transfected with either 
a miRNA mimic or miRNA inhibitor of the studied family member, with 6 replicates in the primary 
round and 11 replicates in the replication/validation round. The Drug Sensitivity Score (DSS) 
(Yadav et al., 2014; Fagerholm et al., 2017) measures the drug response based on miR-30-exposed 
cell viability at increasing drug concentrations. 
Figure 7, and Supplementary Figure 2 in Study IV, illustrate the visual comparison of DSS between 
each miR-30 member compared to its inhibitor per cell line in the primary and replication rounds, 
respectively. In the first round of screening, all of the miR-30 family members sensitized (indicated 
by higher DSS) HCC1954 (the HER2+ cell line) to HER2-targeted lapatinib compared to their 
corresponding inhibitors with p-values varying between 1.5e-03 to 9.3e-05. The effect was 
reproduced in the replication round with p-values varying between 1.2e-02 to 4.2e-15. In the 
HCC1937 (the triple negative, p53-deficient cell line), all miR-30 mimics strongly sensitized the 
cell line to doxorubicin compared to miR-30 family member inhibitors with p-values varying 
between 1.3e-05 to 4.8e-08. In the replication round, all miR-30 members presented a similar effect 
with the largest p = 7.5e-07. A consistent effect was observed in the MDA-MB-361 (the luminal-
like, p53-deficient, HER2+ cell line), with all miR-30 members sensitizing the cells to doxorubicin 
compared to their inhibitors in the primary (largest p < 10-4) and replication (largest p < 10-6) 
rounds. In MCF7 (the luminal-like, p53-proficient, HER2- cell line), miR-30 members showed an 
opposite effect, i.e. the miR-30 mimics decreased doxorubicin sensitivity compared to their 
inhibitors. However, only miR-30d (1.1e-03) and miR-30e (4.9e-02) reached statistical significance. 
In the replication round with a higher number of replicates, the effect was more pronounced with p-
values between 0.11 and 1.4e-06. In the replication/validation round, we added two more basal-like, 
p53-deficient cell lines (MDA-MB-436 and CAL-120) to those included in the primary round. In 
both cells, all miR-30 members increased the cells sensitivity to doxorubicin compared to their 
corresponding inhibitors with the largest p = 9.4e-15 and p = 2.5e-06 in MDA-MB-436 and CAL-
























































Figure	 7.	 Drug	 sensi2vity	 scores	 (DSS)	 for	 breast	 cancer	 cell	 lines	 transfected	 with	 miR-30	 family	





5.4.4 Association with gene expression level, and functional annotation  
To investigate the association between the miR-30 family members and the expression level of the 
genes, the publicly available METABRIC breast cancer dataset was applied to 1,302 breast tumors 
(Dvinge et al., 2013) with two parallel approaches: MicroRNA Target Filter analysis and the Core 
analysis. For the MicroRNA Target Filter analysis, only the negatively correlated genes were 
included in the analysis, assuming that the miRNA function on mRNA-level is repressive, whereas 
in the Core analysis, all correlated genes were included. The Ingenuity Pathway Analysis (IPA, 
QIAGEN N.V., Venlo, The Netherlands) was used to study the pathway enrichment analysis. 
Consistent in both Target and Core analyses, the set of genes correlated with miR-30 family 
members were strongly enriched in pathways of cell migration, motility, and cytoplasmic 
development. See Supplementary Table 4 in Study IV for the detailed number of correlating genes 






While the impact of germline variation on breast cancer risk has been largely investigated, our 
understanding of the role of hereditary components in patient’s survival and therapy outcome 
remains incomplete. This work aimed to identify molecular prognostic and predictive markers of 
breast cancer by screening cancer-related networks (TP53 and NF-κB), and by studying candidate 
genes in regulatory networks of microRNAs (miR-30 family) and candidate proteins (NQO1 and 
NF-κB), for their potential contribution to breast cancer survival and treatment outcome. A previous 
study by Fagerholm et al. (2008) identified an SNP in NQO1, rs1800566, which reduces the protein 
half-life, to predict decreased breast cancer patients’ survival, especially after anthracycline-based 
chemotherapy and in p53-positive (aberrant) tumors. Their findings suggested that NQO1 modifies 
the anthracycline-based treatment outcome, possibly through a p53 and TNF-NF-κB pathway. That 
prompted Studies I, II and III to be conducted, investigating the prognostic and predictive potentials 
of TP53, NF-κB and NQO1, along with the genes involved in their networks. Following the 
evidence shown by Li et al. (2012) on the association of miR-30d expression with poor clinical 
outcome in ovarian cancer patients, Study IV was conducted to investigate the prognostic and 
predictive value of miR-30d, and its family members, in breast cancer. 
 
6.1 TP53 network genes 
Study I examined the prognostic association of germline variations in the TP53 network genes, 
PRKAG2, PPP2R2B, CCNG1, PIAS1 and YWHAQ, which previously had been suggested to modify 
predisposition to cancer development or patients’ survival and drug response (Vazquez et al., 2008, 
2010). Additionally, TP53 R72P and MDM2 SNP309 variants were investigated for their 
interaction with the variant in the studied genes following the previous reports on their implication 
on breast cancer patients’ survival (Tommiska et al., 2005; Schmidt et al., 2009). The variants were 
also studied for their association with pathological characteristics of the tumors. Two variations in 
the PRKAG2 gene, PRKAG2-01 (rs1029946) and PRKAG2-02 (rs4726050), showed suggestive 
evidence for improved patient survival, however, the effect appeared to be driven by the HEBCS 
study. The PRKAG2-01 (rs1029946) rare G allele emerged as a predictor of survival in the pooled 
data independently of the conventional prognostic factors, age of diagnosis, and study. For the same 
SNP, carriership of GG genotype was found to associate with TP53-immuno-negative tumors. 
PRKAG2 encodes AMPKγ, the gamma-2 regulatory subunit of AMP-activated protein kinase, 
which is a highly conserved metabolic sensor across eukaryotes maintaining energy homeostasis 
(Garcia et al., 2017) and a regulator of TP53 (He et al., 2014) under metabolic stress. AMPK might 
have a contextual tumor suppressor role by activating the cell cycle arrest or senescence through its 
interaction with TP53 under glucose shortage. AMPK is reported to activate TP53 by 
phosphorylating on Serine 15 in low glucose condition to promote G1/S cell cycle arrest (Jones et 
al., 2005); however, whether that is sufficient for TP53 activation is not confirmed (Chao et al., 
2000; He et al., 2014). Under the glucose starvation mode, continuous activation of AMPK 
provokes TP53-dependent cellular senescence (Jones et al., 2005). In contrary to the plausible 
tumor suppressor-like impact of AMPK under metabolic stress, it has been suggested that under 
hypoxia, AMPK pathways may provoke cell survival by favoring adaptation to stressed conditions 
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in order to maintain energy homeostasis at cellular and body levels (Garcia et al., 2017), possibly by 
an anti-apoptotic mechanism through LKB1-AMPK interplay. LKB1 plays a central role in 
maintaining the homeostatic ratio between ATP and AMP via AMPK to inhibit the initiation of 
apoptosis, thus in this context, LKB1-AMPK exerts a proto-oncogenic function (Jeon, Chandel & 
Hay, 2012; Laderoute et al., 2006; Lee et al., 2015).  
In this context, the association between the rare G allele and improved survival could be interpreted 
in keeping with the AMPK cell survival function. Interestingly, the gene expression analysis of 
PRKAG2 in the HEBCS dataset showed a direct association between high expression of PRKAG2 
and decreased breast cancer patients’ survival (plog-rank test = 0.014) (Supplementary Figure 1 in 
Study I). However, in the microarray dataset of 187 breast cancer cases, no significant correlation 
was found between the PRKAG2-01 (rs1029946) rare G allele and the expression of the gene. Both 
of the PRKAG2 SNPs lie within the intronic regions of the genes without any predicted effect on the 
protein sequence, however, PRKAG2-02 (rs4726050) is in linkage disequilibrium with PRKAG2 
(rs2727567) which was suggested to modify drug response in vitro (Vazquez et al., 2008). 
In the test for interaction, a significant (p = 0.001) dose-dependent interactive effect of the 
PRKAG2-02 (rs4726050) with MDM2 SNP309 emerged as a modifier of patients’ survival. 
Improved patients’ survival by PRKAG2-02 (rs4726050) was confined to the cases with MDM2 
SNP309 (TG/GG) genotype. While patients’ survival did not differ by MDM2 SNP309 genotypes 
alone in this study and previous publications (Schmidt et al., 2009; Toyama et al., 2007; Boersma et 
al., 2006), and only changed with borderline significance (p = 0.049) by PRKAG2-02 (rs4726050), 
the observed effect is likely due to a combined effect. Also, the interaction term emerged as a 
significant predictor of patients’ survival in a multivariate Cox regression model including the 
SNPs’ main effect as well as the interaction term (p = 0.047). SNP309 is a G to T change in the 
regulatory region intron 1, which directly correlates with the elevated expression of MDM2 which is 
a well-documented negative regulator of TP53 (Bond et al., 2004; Karni-Schmidt, Lokshin & 
Prives, 2016).  
An interaction between MDM2 SNP309 GG genotype and TP53 72Pro (compared to Arg72) variant 
was previously shown to associate with poor patient survival (Schmidt et al., 2009), which is in 
keeping with MDM2 SNP309 increasing the MDM2 level and the Arg72 variant (compared to 
72Pro) inducing apoptosis and increasing the pro-apoptotic TP53-regulated genes (Jeong et al., 
2010). The underlying mechanism of the observed interaction between PRKAG2 (AMPKγ) and 
MDM2 and how it may affect patients’ survival cannot be hypothesized here; however, the result of 
this study suggests that the genetic variations affecting the major player of metabolic and energy 
homeostasis, PRKAG2/AMPK, in combination with MDM2 SNP309, may have an impact on TP53 
function and therefore cell survival in breast cancer tumors. 
Furthermore, there was suggestive evidence for the association of PPP2R2B (rs10477313) AA/AG 
genotype with improved patient survival (p = 0.034) especially among subgroups based on 
hormonal therapy (p = 0.014). The SNP was a predictor of improved hormonal therapy outcome 
independently from the conventional prognostic factors. Another PPP2R2B SNP, rs319217, was 
previously reported to associate with breast cancer recurrence after hormonal therapy (Vazquez et 
al., 2011). Additionally, the gene expression analysis of PPP2R2B in Study I showed association 
with patients’ survival, with PPP2R2B low expression correlating with decreased patients’ survival 
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(plog-rank test = 0.014) (Supplementary Figure 2 in Study I), which is in line with the suggested tumor 
suppressor-like function of PP2A. Also, the carriers of AA genotype were frequently among the 
PR-negative tumors. PPP2R2B encodes the regulatory B subunit of the Ser/Thr protein phosphatase 
2A (PP2A), which regulates the phosphorylation of proteins involved in cell cycle, DNA 
replication, cell mobility and apoptosis, and is often inactivated in cancer cells by phosphorylation 
of Tyr-307 (p-PP2A) (Seshacharyulu et al., 2013). Reduced expression of PP2A occurs in multiple 
cancer types including those of the breast, often through the promoter hypermethylation (Muggerud 
et al., 2010). The PP2A complex functions as an inhibitor of signal transduction in the 
PI3K/AKT/mTOR pathway (Ruvolo, 2016), which is frequently over-activated in cancer cells. 
Additionally, PP2A activation demonstrated synergy with the inhibitors of PI3K/AKT/mTOR, and 
their combination resulted in increased cell death of pancreatic cancer cells in vitro and in vivo 
(Allen-Petersen et al., 2019).  
Given that the aberrant PI3K/AKT/mTOR signaling pathway is among the aromatase inhibitors 
(AIs) resistance mechanisms (Yamnik et al., 2009; Mills, Rutkovsky & Giordano, 2018), it could 
have been presumed that PP2A activation might play a role in AI efficacy. Also, AI resistance 
occurs by the phosphorylation of ERα serine 167 (Ser167), and recent studies showed that the 
upregulation of PP2A suppresses the Ser167 phosphorylation in an estradiol-dependent manner 
(Hayashi et al., 2017) which lend further support to the potential relevance of PP2A in hormonal 
therapy of breast cancer also suggested by the results found in Study I. Overall, Study I provides 
further evidence for the implications of the genetic variations in genes involved in the TP53 
network as potential prognostic and therapeutic markers of breast cancer. 
 
6.2 NF-κB network genes 
A two-SNP interaction analysis was performed to evaluate the plausible epistatic/non-additive 
interactive effects of 917 germline variations in 75 genes involved in the NF-κB activating pathway. 
The study applied a semi-parametric approach, a large BCAC sample size of n=30,431, and 
stringent p-value and hazard ratio criteria driven from the power analysis for each model of 
inheritance. Two SNP pairs, rs5996080-rs7973914 (in chromosomes 22 and 12, respectively) and 
rs17243893-rs57890595 (in chromosomes 9 and 8, respectively), were identified to associate with 
patients’ survival under the recessive and dominant model of inheritance, respectively. None of the 
SNPs alone showed statistically significant survival effect. 
For the recessive SNP pair, rs5996080-rs7973914, the carriership of the homozygous rare allele of 
both SNPs associated with decreased 10-year overall survival compared to carriers of at least one 
common allele. No correlation was observed between the interacting genotype combination and 
tumor’s pathological characteristics, which could be partially due to the limited number of the 
concomitant rare homozygous genotype of both SNPs in each category. The NF-κB related loci 
represented by the recessive SNP pair include BAFFR, indicated by rs5996080 at 31.5kb 




The SNP inclusion criteria in this study involved the variations within or in the 50kb flanking 
region of genes in the major NF-κB activating pathway. However, physically, rs5996080 lies in the 
intron of SREBF2 (sterol regulatory element-binding transcription factor 2), and rs7973914 is 
located in the intron of SCNN1A (sodium channel non-voltage-gated 1 alpha subunit). SREBF2 
encodes SREBP2 of SREBP transcription factor family proteins, which are necessary for cholesterol 
homeostasis (Ricoult et al., 2016). Little has been reported on the association between SREBP2 and 
breast cancer, particularly in an NF-κB dependent manner. However, a study in liver cancer cells 
showed that lipopolysaccharide (LPS), found in the outer membrane of gram-negative bacteria, and 
which can trigger inflammatory responses, enhances the cholesterol accumulation by upregulating 
SREBF2 through the NF-κB signaling pathway (He et al., 2017). As for SCNN1A, which hosts the 
other SNP in the pair (rs7973914), its aberrant expression level, associating with extensive DNA 
hyper-methylation, has been shown by an epigenetic biomarker analysis in a cohort of primary 
breast cancer. Moreover, the SCNN1A protein level appeared to be normal in luminal-like tumors, 
whereas it was reduced in triple negative subtypes (Roll et al., 2013).  
In keeping with the interactive association of the two loci represented by this SNP pair, Study II 
also identified an rs5996080 proxy (rs5996088 r2 = 1) which correlated with lower expression of 
both SREBF2 and SCNN1A (p = 0.014 and p = 0.0007 respectively; TCGA dataset only). Similarly, 
rs5996080 proxies showed significant correlation with the expression level of both of the candidate 
NF-κB related genes in the same loci, i.e. BAFFR and TNFR1/3, represented by the recessive SNP 
pair. 
The protein product of BAFFR is a specific receptor of BAFF, which is a pivotal component for the 
survival of maturing B lymphocyte, and an activator of the non-canonical NF-κB pathway (Zhang, 
Lenardo & Baltimore, 2017). NF-κB1 and NF-κB2 encode p105 and p100, respectively, which are 
processed to the active forms of p50 and p52 NF-κB subunits, respectively. BAFF/BAFFR play a 
major role in promoting the processing of RelB/P100 to ReLB/P52 through the stabilization of the 
IKK complex in a NEMO-independent manner (non-canonical pathway) (Claudio et al., 2002), 
resulting in translocation of NF-κB2 into the nucleus and its corresponding pro-survival effects 
(Figure 3 in Study II).  
While the BAFF-induced inflammatory background in cancer patients has been postulated to 
associate with cancer cachexia (Rihacek et al., 2015), its role in breast cancer development and the 
clinicopathological characteristics and evolution of the disease remains to be elucidated. A small 
immunohistochemistry study on 52 human breast cancer samples found no differential expression 
of BAFF among normal and cancer tissues. Also, BAFF expression did not associate with disease-
free survival or the overall survival of patients (Pelekanou et al., 2008). Similarly, in Study II, the 
SNP representing the BAFF receptor did not show any survival association alone. It has been 
suggested that BAFFR, along with BCR (B cell antigen receptor), influence NF-κB activation also 
through the canonical pathway; however, the magnitude of its impact is yet to be investigated 
(Siebenlist, Brown & Claudio, 2005; Morrison et al., 2005).  
The other genes represented by the recessive SNP pair, TNFR1 and TNFR3, encode for receptor 
types 1 and 3, respectively. Similarly to BAFFR, these are transmembrane glycoproteins and 
members of the TNF receptor superfamily (Fuchs et al., 1992; Sennikov et al., 2014). In response to 
their corresponding form of TNFα ligands, TNFR1 and TNFR3 activate the canonical or non-
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canonical NF-κB pathway which, depending on the cellular context and the protein domains of the 
molecular mediators involved, results in promoting proliferation, apoptosis, or increased 
cytotoxicity (Figure 3 in Study II) (Zhang, Lenardo & Baltimore, 2017; Wajant, Pfizenmaier & 
Scheurich, 2003). Given that many biological impacts of TNFα are realized through TNFR1, it 
could be postulated that the alteration in the function of this protein and its interacting partners may 
disturb the dynamics between the pro- and anti-survival NF-κB signaling pathways, which may 
consequently modify cancer progression, possibly in an epistatic manner. Although the underlying 
mechanism of the SNP-SNP interaction effect observed here can only be speculated at this point, 
the association between the recessive SNP pair or their proxies, particularly rs5996080, with the 
expression level of both BAFFR and TNFR1/3 lends further support to the possible combined effect 
of the represented loci on patients’ survival. While the result of this study is in line with the 
suggested pro-survival role of BAFF/BAFFR and TNFR1/3 (Almaden et al., 2014; McClements et 
al., 2008; Legler et al., 2003), all these receptors have also been shown to induce anti-survival 
signals depending on the involved receptor interactive proteins, particularly TNFα which is 
essentially a pleiotropic cytokine (Hehlgans & Pfeffer, 2005; Hsu, Xiong & Goeddel, 1995; Hsu et 
al., 1996). It could be presumed that the controversies may also be due to the complexity of the 
pathway itself as well as the diverse biological effects of its stimuli. 
For the dominant SNP pair, rs17243893 and rs57890595, the carriership of at least one rare allele 
for both SNPs improved 10-year breast cancer survival compared to the carriers of the homozygous 
wild-type genotypes. Patients’ survival did not differ by either of the SNPs alone. In line with the 
survival result, the protective genotype combination associated with negative nodal status, and 
negative distant metastasis at diagnosis. 
The first SNP of the pair, rs17243893, lies in the intronic region of TRAF2, which encodes TRAF2, 
a frequent target of pro-inflammatory and tumor-derived mediators and activators of the NF-κB 
signaling pathway (Shen et al., 2015). Upon activation of the upstream TNF receptors, TRAF2 
forms a multimeric complex which initiates a kinase cascade to transduce the NF-κB activating 
signal through the IKK complex (Zhao et al., 2015). Several studies implicated the role of TRAF2 
in cancer (Thomas et al., 2009; Wood et al., 2012), including its upregulation in the malignant 
pleural effusion cells in human breast cancer and its association with decreased patient survival 
(Zhao et al., 2015). Another study has reported the elevated copy number of TRAF2 in epithelial 
cancers, including those of the breast (Shen et al., 2015).  
The other SNP in the dominant pair, rs57890595, resides in the intron of TRAIL receptor TRAIL-
R4, which is involved in the activation of the NF-κB pathway through a TRAF2-NIK-IKK complex 
(Figure 3 in Study II), which results in pro- or anti-apoptotic outcomes depending on the TRAIL 
receptor from which the signal originates (Lalaoui et al., 2011; Nguyen et al., 2018). In brief, 
TRAIL-R1/2 induce cell death signals, whereas TRAIL-R4 seems to be restricted to non-apoptotic 
pathways. It can be presumed that the anti- or pro-survival signal transduced through the TRAIL 
receptors bifurcate at the TRAF2 step which, in addition to the often reported pro-survival effect of 
TRAF2 and TRAIL-R4, is consistent with the observed interaction between the carriership of the 
combined rare allele and improved patients’ survival in Study II. However, the study conclusion is 
also limited because none of the SNPs in the dominant pair, nor their proxies, were represented in 
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the METABRIC/TCGA database to evaluate the association between this pair and TRAIL-R4 and 
TRAF2 expression.  
Another weakness of this study is the potential data interpretation biases generated by pathway-
based SNP selection: the regulatory association of the selected SNPs may extend beyond their cis 
haplotype and thus, the causal gene exerting the observed survival association may not have been 
integrated in the study hypothesis. To address this problem within the means of this study, a 
genome-wide gene expression association study was performed for the studied SNPs and their 
proxies, and no significant correlation was observed with other genes elsewhere. However, since the 
SNP pairs in the recessive model are physically located in two other genes in the same loci, 
SREBF2 and SCNN1A, and in light of the observed correlation between an rs5996080 proxy 
(rs5996088) with the expression of SREBF2 and SCNN1A, as well as BAFFR and TNFR1/3, the 
interaction effect cannot be exclusively attributed to the NF-κB genes. Furthermore, large-scale 
analyses are potentially at risk of inflated type I error. To limit the probability of false positive 
results, the study power was calculated to define robust HR thresholds, and appropriate multiple 
testing correction methods were applied. 
 
6.3 NQO1 and NF-κB  
 
A study by Fagerholm et al. (2008) found strong association between the homozygous missense 
variant of NQO1 (rs1800566, P187S) and patients’ survival, especially in the subset of patients who 
received anthracycline-based chemotherapy and among the cases with TP53-positive 
immunohistochemistry (suggestive of mutant TP53). The homozygous rare T allele disables NQO1 
activity and possibly disturbs its ability to stabilize major stress response proteins such as TP53 or 
to regulate the NF-κB pathway (Asher et al., 2005).  
Study III analyzed the immunohistochemical staining of NQO1 expression and NF-κB nuclear 
localization in two series of breast cancer tumors for prognostic, predictive, and clinicopathological 
association. No significant impact on patients’ survival or treatment outcome was observed by the 
expression of NQO1 or the nuclear localization of NF-κB (inferred activity). However, an inverse 
correlation was found between NQO1 expression and NF-κB nuclear localization. The inverse 
pattern of correlation was also seen in their association with ER status of the tumors, i.e. negative 
NQO1 expression and positive NF-κB nuclear localization were found more frequently in ER-
negative tumors than in ER-positive tumors. Consistently, the adverse correlation between NQO1 
and NF-κB was also reflected in the microarray gene expression analysis results, as well as the 
functional annotation of the associating genes. Interestingly, among the genes which positively 
correlated with NF-κB, and thus negatively with NQO1, were genes involved in the immune 
response as well as those which are NF-κB nuclear import promoting factors such as TNF, TNF-
related genes and TLR-related genes (Zhang, Lenardo & Baltimore, 2017). Of genes which 
positively correlated with NQO1, and negatively with NF-κB, were those implicated in cellular 
processes of oxidation/reduction, and steroid metabolism consistent with the published functions of 
NQO1 and the results of this study.  
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Moreover, the gene expression analysis revealed the co-upregulation of NQO1 and multiple genes 
involved in steroid metabolism (Figure 4 and Supplementary Table 6 in Study III), which is in line 
with the observed association between NQO1 and ER expression in breast cancer tumors. This was 
also in line with previously published regulatory crosstalk between ER and NQO1 (Carroll et al., 
2006), but in contrary to the reported inverse regulatory relationship between ER and NRF2, a 
positive transcription factor of NQO1 (Mutter, Park & Copple, 2015; Yao et al., 2010). 
Additionally, tumors with nuclear expression of NF-κB were frequently ER-negative, which is 
consistent with the published mutually-suppressing crosstalk between ER and NF-κB (Biswas et al., 
2004). Several studies had reported the co-activation of NQO1 and NF-κB in normal and skin 
cancer cells (Cheng et al., 2010; Iskander et al., 2006; Ahn et al., 2006).  
The results of Study III point to an inverse correlation between the two proteins, which might be 
explained by their suggestive opposite connection with ER signaling in breast cancer. The adverse 
correlation may also be due to the molecular link between NQO1, NF-κB and TP53. Indeed, it has 
been shown that TP53 degradation, induced by NQO1 deficiency, elevates the nuclear level of NF-
κB in prostate cancer cells, possibly by competing for the limited pool of their transcriptional co-
activator proteins, p300 and CBP (Thapa et al., 2014). Nevertheless, in-depth functional follow-up 
is required to confirm and investigate the biological explanation behind the reverse correlation 
observed here. 
 
6.4 miR-30 family 
In Study IV, the miRNA in situ hybridization was applied to analyze the cytoplasmic expression of 
miR-30d for its relation to clinicopathological and survival data in 1,238 human breast cancer 
tumors. High expression of miR-30 was a predictor of longer metastasis-free survival and breast 
cancer survival, independently of the conventional prognostic markers. The survival association 
was especially pronounced among subgroups with Ki67 positivity (inferred high proliferation), with 
ER negativity, those who received chemotherapy, and among patients with HER2-positive tumors.  
On the basis of the observed survival association of miR-30d by HER2 status and the suggestive 
evidence of its association with anthracycline-based therapy outcomes, and given that all the miR-
30 family members (miR-30a–e) share the mature seed regions, the study further investigated the 
impact of all miR-30 members on response to lapatinib and doxorubicin in vitro. The association 
between high expression of miR-30d and improved survival in HER2-positive subgroups was in 
keeping with the miR-30 family members sensitizing the HER2+ HCC1954 cell line to lapatinib. 
Considering that in breast cancer the TOP2A amplification usually occurs with HER2 
amplification, and given that TOP2A is the primary target of anthracycline-based drugs (Brase et 
al., 2010; Arriola et al., 2007; Di Leo et al., 2002; Villman et al., 2006; Jacot et al., 2013), it could 
be postulated that a miR-30/HER2/TOP2A axis in breast cancer tumors may influence doxorubicin 
(anthracycline-based agent) sensitivity, as well as the lapatinib response due to its HER2-targeting 
mechanism. In the subset of patients receiving anthracycline-based chemotherapy, high miR-30d 
associated with improved patient survival. In the drug sensitivity screening, the miR-30 family 
member mimics strongly sensitized the breast cancer cell lines to doxorubicin compared to their 
inhibitors. This result is in line with previous studies reporting the inhibition of chemoresistance by 
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miR-30 family members in a variety of cancers, including those of the ovaries (Sestito et al., 2016) 
and breast (Fang et al., 2014; Bockhorn et al., 2013).  
In this study, the effect of miR-30 members on drug sensitivity was consistent in all of the cell lines 
except for MCF7 which exhibited an opposite effect, i.e. the miR-30 family member mimics 
decreased cell line sensitivity to doxorubicin compared to their inhibitors. Given that MCF7 is the 
only p53-proficient cell line in the screening, it can be postulated that the observed opposite effect 
might be associated with its p53 status. In the survival analysis, high miR-30d also associated with 
better survival among patients with p53+ (mutated) tumors. The TP53 mRNA expression and 
protein activity were not available in the METABRIC dataset to further analyze the miR-30 family 
and p53 activity. However, several lines of evidence have demonstrated miR-30a as the direct target 
of p53, and its reduced expression has been reported to associate with poor patient survival (Guo et 
al., 2016; di Gennaro et al., 2018, 2019). Additionally, it has been suggested that p53 inhibits the 
expression of ZEB2, a transcriptional factor involved in EMT (a key molecular step of metastasis) 
(Mittal, 2018), through miR-30a to control tumor cells’ invasion and dissemination (di Gennaro et 
al., 2018, 2019). Here, the pathway enrichment analyses found a negative correlation between miR-
30 and genes involved in cell motility and migration, which is also in line with our clinical findings 
of high miR-30d association with longer metastasis-free survival.  
Several studies suggest that miR-30 family members inhibit cell migration and invasion by 
suppressing EMT and cell mobility phenotypes in cancers, including breast carcinoma (Zhang et al., 
2014; Kao et al., 2014; Cheng et al., 2012), particularly through their interaction with SNAI1 and 
SNAI2 (Kumarswamy et al., 2012; Zhou et al., 2013) and metadherin (Zhang et al., 2014). 
Furthermore, our findings in breast cancer contradict the study by Li et al. (2012) in ovarian cancer, 
which suggested an inverse association between high miR-30d expression and ovarian cancer 
patients’ survival. It appears that the association between miR-30 family members and cancer 
prognosis, as well as metastasis, might be tissue-dependent and cancer-specific. For instance, unlike 
in breast cancer, miR-30 family members have been shown to induce metastasis in melanoma 
(Gaziel-Sovran et al., 2011) and hepatocellular carcinoma (Yao et al., 2010). Thus, the connection 
between miR-30 expression and the magnitude of tumor malignancy and patients’ survival appears 
to be cancer-specific.  
A weakness of this study is the absence of endogenous miR-30 expression measurement in the drug 
sensitivity screening, which could have provided a more accurate setting for comparison of the 
miRNA effect among cell lines, especially between the p53 deficient and proficient cells, as well as 
among HER2+ and HER2- cell lines. Nevertheless, the postulated connection between the miR-30 
effect on drug screening through the HER2/TOP2A axis or p53 and cell migration connection must 
be viewed as hypothesis generating. Whether the clinical findings of this study are caused by miR-
30-induced drug sensitivity due to a plausible connection to proliferation and the HER2/TOP2A 
axis, p53 status of the tumor cells, or to the postulated anti-metastatic function of miR-30 remains 





7 Summary and conclusions 
The aim of this thesis was to identify molecular prognostic and predictive markers in breast cancer. 
Taking two approaches of network screening, and candidate gene study, this work has investigated 
cancer-related networks (TP53 network, NF-κB activating network), candidate NQO1 protein, and 
miR-30 family members, to identify prognostic and predictive markers of the disease that could be 
used to identify subgroups of patients who do or do not benefit from chemo- or endocrine therapy 
options.  
For years the role of TP53 in breast cancer, and cancers in general, has been under extensive 
investigation. While the impact of somatic TP53 mutation in breast cancer risk is rather well 
established, the clinical relevance of germline mutation in TP53 as a modifier of patients’ survival 
is yet to be clarified (Schon & Tischkowitz, 2018). Given the complex activities of TP53 and its 
large network of interacting genes, which influence major cancer-related phenotypes, and on the 
basis of previous evidence suggesting clinical implications for TP53 network genes (Vazquez et al., 
2011) and their interaction (Schmidt et al., 2009), this study investigated the association between 
candidate TP53 related genes and patients’ survival and therapy outcome. The survival analysis of 
4,701 invasive breast cancer cases found evidence of superior 10-year overall survival for patients 
carrying the rare alleles of PRKAG2 (rs4726050) (driven by HEBCS) and PRKAG2 (rs1029946), 
and the interaction between PRKAG2 (rs4726050) with MDM2 SNP309 emerging as a significant 
modifier of patients’ survival. Additionally, increased patient survival after hormonal therapy was 
predicted by an SNP in another TP53 network gene: PPP2R2B (rs10477313). However, the rare 
allele of rs10477313 also showed borderline significant correlation with PR negativity, i.e. more 
often among tumors with a PR-negative receptor. The result of this study warrants further research 
to investigate and validate the observed effect (Jamshidi et al., 2013). 
A two-SNP interaction analysis of germline variations in NF-κB activating pathways among 30,431 
invasive breast cancer cases found two interacting SNP pairs associating with patients’ survival: 
under the recessive model of inheritance, patients simultaneously homozygous for the rare alleles of 
rs5996080 and rs7973914 had decreased survival, and under the dominant model of inheritance, 
patients carrying at least one rare allele for rs17243893 and rs57890595 showed increased survival. 
The NF-κB related genes represented by these pairs included BAFFR and TNFR1/TNFR3 for the 
recessive SNP pair, and TRAF2 and TRAIL-R4 for the dominant SNP pair. However, the recessive 
SNP pair (rs5996080 and rs7973914) physically reside in two other genes in the loci, SREBF2 and 
SCNN1A, respectively, and an rs5996080 proxy was found to correlate with the expression of all 
four genes. Therefore, the interacting effect observed under the recessive model cannot be 
exclusively attributed to the NF-κB related genes. The predictive value of the identified SNP pairs 
and the biological explanation behind it warrant further studies and comprehensive functional 
investigations (Jamshidi et al., 2015). 
An immunohistochemical analysis of tissue microarray in two series of 1,240 and 283 Finnish 
invasive breast cancer tumors found an inverse correlation between NQO1 protein expression and 
NF-κB activation, underlined also by inverse patterns of association with ER and gene expression 
profiles of tumors, which might be cancer-specific. Neither NQO1 protein expression nor NF-κB 
nuclear localization emerged as significant predictors of patients’ survival (Jamshidi et al., 2012). 
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A microRNA in situ hybridization analysis in 1,238 Finnish invasive breast cancer tumors found 
that while high expression of miR-30d correlates with highly proliferative tumors, it also strongly 
predicts longer metastasis-free and breast cancer patients’ survival. The survival association was 
particularly evident in subgroups of patients with HER2-positive or highly proliferating tumors 
(estimated by Ki67), and among those who have received chemotherapy. In a drug sensitivity 
screening, miR-30 family members sensitized the breast cancer cell lines to doxorubicin and 
lapatinib. In the pathway enrichment analysis, the top function of the genes correlating with miR-30 
family members was cell movements, which is in line with the observed association between high 
miR-30d and longer metastasis-free survival, as well as the previously published profile of the miR-
30 family. These results suggest that the expression of miR-30 family members may contribute to 
the prognosis of breast cancer and to the therapy response in a cancer-specific manner. However, 
estimating the extent of their impact and their predictive value requires further studies. 
This work provides suggestions for the potential of germline variants, and their interactions, in 
TP53 and NF-κB network genes, as well as the expression of miR-30 family members to impact the 
prognosis of breast cancer and treatment outcome. The findings of this study warrant further 
investigation. Future association studies followed by in-depth functional investigations can 
accelerate the identification of objective predictive and prognostic markers of breast cancer. In turn, 
the discovery of robust predictive markers will facilitate therapeutic decisions and improve patients’ 
care. In general, if further validated and approved reliable, the identified biomarkers might benefit 
three groups: (1) patients would benefit from personalized and sufficient therapy and avoid the 
toxicity and side-effects of unnecessary treatments; (2) physicians would be able to customize 
treatment to each patient’s need in a shorter time; and (3) clinics could reduce treatment costs by 
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